The Biochemical, Hematological, and Radiological Evaluation of the Hemodialysis Patient: An Evidence-Based Look at Quality, Screening, and Treatment

A Critical Appraisal of What We Monitor, Why We Monitor It, and Whether It Actually Improves Outcomes

Medical Associates Department of Nephrology | University of Illinois College of Medicine at Peoria | University of Dubuque Physician Assistant Program | Butler College of Osteopathic Medicine

Executive Summary

Hemodialysis patients occupy a unique physiologic space. Standard screening tests — developed and validated in populations with normal kidney function, intact erythrocyte survival, and decades of remaining life expectancy — require fundamental modification when applied to the ESKD population. The alterations run deeper than simple frequency adjustments. In many cases, the tests themselves become unreliable, the interventions they would trigger become ineffective, and the time horizon for benefit shrinks to the point where screening causes net harm.

This review synthesizes evidence from KDIGO, ADA, CDC/ACIP, ASN, KDOQI, and major randomized controlled trials — including HEMO, ESHOL, CONVINCE, CHOIR, CREATE, TREAT, EVOLVE, and IMPROVE-CKD — to provide a structured, evidence-based framework for the biochemical, hematological, and radiological evaluation of the maintenance hemodialysis patient. The central thesis is that many dialysis quality metrics predict comorbidity burden but do not improve outcomes when the metric itself is changed by intervention.

Screening and Monitoring

Lipid management follows a “fire-and-forget” strategy. 4D, AURORA, and SHARP demonstrated no cardiovascular benefit from statin initiation in prevalent HD patients. KDIGO 2013 recommends against initiation on dialysis while supporting continuation of pre-existing therapy; the KDIGO 2024 CKD guideline excludes people receiving dialysis [1-4].
HbA1c is systematically unreliable in HD. Shortened erythrocyte lifespan, ESA use, and carbamylated hemoglobin underestimate true glycemia by approximately 25 mg/dL. KDIGO 2022 keeps HbA1c as the primary marker and supports CGM when HbA1c is discordant [33]; CGM is the most direct glycemic tool, and glycated albumin is an alternative that avoids red-cell bias but carries its own [5-9,36].
CKD-MBD monitoring follows KDIGO 2017 — but the EVOLVE trial (cinacalcet) failed its primary composite endpoint despite lowering PTH, and IMPROVE-CKD showed no vascular calcification benefit from phosphate binders. Phosphorus-mortality association is modified by albumin status; phosphorus variability predicts mortality independently [10,11,85,86,87,88].
Hepatitis, thyroid, cancer, ACKD screening — HCV every 6 months; TSH at initiation and annually (11-20% prevalence [14], [16]); cancer screening individualized by life expectancy; ACKD ultrasound beginning at 3 years of dialysis [12-24].
Fish oil supplementation should be considered based on the PISCES trial (1,228 patients, 26 sites, up to 3.5 years of follow-up; 4g omega-3 PUFAs daily — EPA 1.6g + DHA 0.8g vs corn-oil placebo; HR 0.57, 95% CI 0.47–0.70, p<0.001 for recurrent serious CV events [25]; patients with at least one event 20.8% vs 33.7% — ARR 12.9%, NNT 8 over the trial) — the first large placebo-controlled trial to reduce CV events in dialysis since the three statin failures [25].
Depression (20-40%) and cognitive impairment (30-80%) are prevalent, undertreated, and treatment-modifying. PHQ-9 screening at initiation and annually [26-28].

Cardiovascular and Vascular Access Assessment

Echocardiography must include right heart assessment — and should be performed before vascular access creation. In a single-center cohort, 29.4% (10 of 34) of AVF patients who underwent RHC met criteria for high-output cardiac failure [65]. RV dilation post-AVF creation independently predicts mortality (HR 3.9, 95% CI 1.7–9.2) [62]. Access flows >1.5–2.0 L/min or Qa/CO >20–30% are strongly associated with LVH, pulmonary hypertension, and RV failure [55,64].
Vascular access selection must account for cardiac status. Upper arm access carries OR 8.1 for a high access-flow-to-cardiac-output ratio (Qa/CO >0.3) vs forearm [64]. Forearm AVF mean flow is 948 mL/min vs 1,580 mL/min for upper arm [67]. In patients with symptomatic heart failure, CVC demonstrated non-inferior major adverse event-free survival vs AVF [69]. A tiered approach based on EF and RV function — from forearm-first strategies through catheter for EF <15% — replaces the “fistula first at all costs” paradigm [52,53].
Flow reduction techniques (banding, RUDI, DRIL, small-diameter interposition, ligation) show 75–100% symptom resolution rates [70-73]. Tapered grafts do not reduce ischemic steal (VQI n=3,608: HR 1.03) [74].

The Quality Metrics Critique

Kt/V does not improve mortality beyond a minimum floor. The HEMO trial (n=1,846) showed no benefit from higher Kt/V. Meyer et al. (2016) demonstrated that higher Kt/V produced 0% reduction in p-cresyl sulfate and only 22% reduction in methylguanidine [79] — the solutes Kt/V was supposed to represent are not cleared by increasing it [78,79].
Albumin is 21 times more powerful than URR as a mortality predictor (Owen 1993 [76]), and malnutrition carries a pooled mortality HR of 1.49 across dialysis (29 studies, 11,063 patients) and 1.53 in the hemodialysis subgroup [46]. But albumin is driven primarily by inflammation, not nutrition — declines correlate with CRP and IL-6, not with protein intake (nPCR) [89-91]. Low albumin predicts mortality only when accompanied by elevated CRP [92,93]. CRP must accompany every albumin measurement.
The pattern repeats across every major quality metric. Hemoglobin: higher ESA-driven targets caused harm — in hemodialysis, the Normal Hematocrit Trial [103,104]; in non-dialysis CKD, CHOIR (composite CV events) and TREAT (stroke) [82,84] — and pooled, higher targets raised mortality (RR 1.17) [106]. Phosphorus: no placebo-controlled binder trial has demonstrated mortality benefit (IMPROVE-CKD, in non-dialysis CKD, was negative on vascular end points) [85]. PTH: EVOLVE failed [86]. The consistent finding is that fixing the number does not fix the patient.

The Path Forward: High-Volume Hemodiafiltration

HDF addresses what Kt/V cannot. ESHOL (2013): 30% all-cause mortality reduction. CONVINCE (2023): 23% all-cause mortality reduction (17.3% vs 21.9%; ARR 4.6%, NNT 22 over a median 30 months) [95] at convective volumes ≥23 L/session [94,95]. CONTRAST demonstrated that CRP and IL-6 rise on low-flux HD but remain stable on HDF (a 20% per year difference for CRP) [96]. HDF clears middle molecules by convection — the toxin class that Kt/V misses entirely. The relevant dose metric is convective volume, not Kt/V.

1. Lipid Screening and Statin Therapy

1.1 The Lipid Paradox in Dialysis

The dyslipidemia profile in HD patients is not the dyslipidemia that statins were designed to treat. Elevated triglycerides, low HDL-cholesterol, and relatively modest LDL elevations characterize the uremic lipid phenotype — driven by decreased lipoprotein lipase and hepatic lipase activity, apolipoprotein C-III enrichment of circulating lipoproteins, and impaired clearance of triglyceride-rich remnant particles [30].

The paradox runs deeper. Lower total cholesterol in HD patients is associated with increased mortality — the “reverse epidemiology” phenomenon reflecting the confounding influence of malnutrition, chronic inflammation, and protein-energy wasting. The malnutrition-inflammation-cachexia syndrome (MICS) drives down cholesterol while simultaneously driving up cardiovascular risk through pathways that statins cannot address [30,31].

1.2 KDIGO Lipid Guideline Recommendations

The KDIGO 2013 Clinical Practice Guideline for Lipid Management in CKD fundamentally changed the approach to lipid management in dialysis patients. The KDIGO 2024 CKD guideline is not intended for people receiving dialysis, so the 2013 statements remain the operative KDIGO guidance for this population [3,4,31]:

Obtain an initial lipid profile (total cholesterol, LDL, HDL, triglycerides) at CKD diagnosis and at dialysis initiation (1C)
Do not initiate statin or statin/ezetimibe therapy in patients already on chronic dialysis (2A)
Continue statin therapy in patients already taking statins at the time of dialysis initiation (2C)
Follow-up lipid measurements are not routinely required — the guideline endorses a “fire-and-forget” approach, abandoning LDL targets in favor of risk-based prescribing (Not Graded)

1.3 Evidence Base: Why Statins Do Not Work in Dialysis

Three landmark trials established the lack of cardiovascular benefit of statins in prevalent HD patients. 4D and AURORA were powered for their primary end points; SHARP was not powered to assess its dialysis subgroup separately [32]:

Trial	Drug	Population	Primary Outcome	Result
4D (2005)	Atorvastatin 20 mg	1,255 diabetic HD patients	Composite: cardiac death, MI, stroke	RR 0.92 (95% CI 0.77-1.10); p = 0.37. No benefit. [1]
AURORA (2009)	Rosuvastatin 10 mg	2,776 HD patients age 50-80	Composite: CV death, MI, stroke	HR 0.96 (95% CI 0.84-1.11); p = 0.59. No benefit. [2]
SHARP (2011)	Simvastatin 20 mg + ezetimibe 10 mg	9,270 CKD patients (3,023 on dialysis)	Major atherosclerotic events	17% RRR overall (RR 0.83, 95% CI 0.74-0.94; ARR 2.1%; NNT 48 over 4.9 years), but no statistically significant benefit in the dialysis subgroup, which SHARP was not powered to assess (heterogeneity vs non-dialysis p=0.25) [32]

The consistency across three trials, two statins, and over 7,000 dialysis patients leaves little room for ambiguity. LDL lowering works in early CKD. It does not work once patients reach dialysis.

Clinical Pearl

The cardiovascular phenotype in dialysis shifts from atherosclerotic plaque rupture (where statins help) to vascular calcification, myocardial fibrosis, volume-mediated cardiomyopathy, arrhythmia, and sudden cardiac death — pathologies that statins do not address [1,2]. This explains the “statin-resistant” cardiovascular risk profile. The 4D trial was particularly instructive: it enrolled exclusively diabetic HD patients — a population that in the general setting would be expected to derive the greatest statin benefit. It found none.

Clinical Warning

Although initiation of statins is not recommended in prevalent dialysis patients, patients already on statins pre-dialysis should generally continue them. The KDIGO guideline specifically distinguishes between initiation (not recommended) and continuation (reasonable). Discontinuation carries its own theoretical risk of rebound events, though this has not been rigorously studied in dialysis [3].

1.4 Primary vs. Secondary Prevention: The Guideline-Practice Gap

The KDIGO 2013 recommendation against initiating statins in dialysis-dependent CKD (2A) does not distinguish between primary and secondary prevention. The evidence base supports this unified position: the 4D trial enrolled exclusively diabetic HD patients (a high-risk secondary prevention-equivalent population), and AURORA included patients ages 50-80 with substantial baseline cardiovascular disease burden. Neither demonstrated benefit even in subgroups with prior cardiovascular events [1,2].

In practice, however, a significant guideline-practice gap exists:

Scenario	KDIGO Recommendation	Real-World Practice
Primary prevention (no prior CVD events)	Do not initiate statin (2A)	Generally followed
Secondary prevention (prior MI, stroke, revascularization)	Same — do not initiate statin (2A)	Frequently overridden by cardiology
Already on statin at dialysis initiation	Continue statin (2C)	Universally followed

The discomfort with withholding statins for secondary prevention in dialysis reflects the tension between nephrology-specific evidence (4D, AURORA, SHARP dialysis subgroup — all negative) and cardiology practice guidelines (ACC/AHA 2018), which recommend high-intensity statin therapy for all patients with clinical ASCVD without carving out a dialysis exception. Most cardiologists will initiate a statin after an acute MI in a dialysis patient as part of standard post-ACS management, even though the nephrology evidence does not support benefit.

Clinical Pearl

When a dialysis patient has an acute coronary event, the statin is typically started by the cardiology team. The KDIGO guideline supports continuing it at that point. The practical distinction: nephrologists should not proactively initiate statins for primary prevention in prevalent HD patients, but need not fight to discontinue a statin started by cardiology for a legitimate secondary prevention indication — even if the evidence is weak.

1.5 Lipid Monitoring: The “Fire-and-Forget” Approach

The “fire-and-forget” approach applies equally regardless of whether the patient is on a statin for primary or secondary prevention. KDIGO explicitly abandoned LDL targets in CKD, including dialysis. There is no LDL goal to titrate toward [3].

When to check lipids:

Clinical Context	Check Lipids?	Rationale
New HD patient, baseline assessment	Yes — once	Rule out secondary causes; document baseline
Stable HD patient on statin, routine follow-up	No	No LDL target; fire-and-forget
Post-ACS, statin started by cardiology	No (from nephrology perspective)	Cardiology may monitor per their own guidelines
Suspected medication non-adherence	Consider	Adherence assessment
New nephrotic syndrome, hypothyroidism, or liver disease	Yes	Evaluate secondary dyslipidemia
Transplant evaluation	Yes	Many transplant centers require recent lipid panel

Clinical Warning

Ordering routine lipid panels in stable HD patients on statins is a common source of low-value care. The result will not change management — you will not titrate the dose, switch agents, or stop the statin based on an LDL number. Resist the reflex to check “because it’s been a while.”

1.6 Fish Oil: The First Positive Cardiovascular Trial in Dialysis

In a field defined by three consecutive statin failures, the PISCES trial [25] (Lok CE et al., N Engl J Med 2026; published online November 2025) represents a genuine practice-changing event. 1,228 maintenance hemodialysis patients across 26 sites in Canada and Australia were randomly assigned to 4g omega-3 PUFAs daily (EPA 1.6g + DHA 0.8g) versus corn-oil placebo and followed for up to 3.5 years (2,776 patient-years). The primary endpoint — all serious cardiovascular events, recurrences included (cardiac death, fatal and nonfatal MI, fatal and nonfatal stroke, and peripheral vascular disease leading to amputation) — was significantly lower in the fish oil group (HR 0.57, 95% CI 0.47–0.70, p<0.001; event rates 0.31 versus 0.61 per 1,000 patient-days, about 11 fewer events per 100 patient-years) [25]. Patients with at least one event: 20.8% versus 33.7% — ARR 12.9%, NNT 8 over the trial (mean follow-up approximately 2.3 years) [25]. The benefit extended to patients without prior CVD history (HR 0.55, 95% CI 0.40–0.76). All-cause death did not differ significantly (175 vs 195 deaths; HR 0.89); serious bleeding occurred in 4.8% vs 7.6% [25].

UpToDate now suggests fish oil supplements for patients on maintenance dialysis to prevent new and recurrent cardiovascular events (Grade 2B; topic updated November 2025, verified 2026-09-26), while noting that confirmatory trials are warranted. KDOQI 2020 predates PISCES and suggests not routinely prescribing long-chain n-3 PUFA to lower mortality (2C) or cardiovascular events (2B) in hemodialysis [116]. PISCES is the first large placebo-controlled trial to show cardiovascular event reduction specific to the dialysis population; a 114-patient carvedilol trial in dialysis patients with dilated cardiomyopathy preceded it [25,115].

Clinical Pearl

Fish oil is thought to act through mechanisms distinct from LDL lowering — proposed anti-inflammatory, anti-arrhythmic, and triglyceride-lowering pathways; PISCES did not establish which one operates [25]. These align better with the cardiovascular phenotype of dialysis (arrhythmia, inflammation, vascular calcification) than the atherosclerotic plaque stabilization that statins provide.

Section Summary

Lipid management in HD follows a “fire-and-forget” strategy with no routine monitoring after baseline. Three landmark trials (4D, AURORA, SHARP dialysis subgroup) established that statin initiation in prevalent dialysis patients provides no cardiovascular benefit, and KDIGO 2013 remains the operative guidance (the KDIGO 2024 CKD guideline excludes dialysis). Continue statins started pre-dialysis. The PISCES trial [25] is the first large placebo-controlled CV prevention trial in dialysis to succeed, supporting consideration of fish oil supplementation for maintenance HD patients. Routine lipid panels in stable HD patients on statins are low-value care.

2. Hemoglobin A1c: The Unreliable Marker

2.1 Why HbA1c Fails in Hemodialysis

HbA1c reflects average blood glucose over the 90-120 day erythrocyte lifespan. In HD patients, that lifespan is shortened to 60-90 days, and multiple additional factors conspire to make HbA1c unreliable [5-7]:

Factor	Effect on HbA1c	Mechanism
Shortened RBC lifespan (uremia)	Falsely low	Less time for hemoglobin glycation
ESA therapy	Falsely low	Increased reticulocyte fraction with young, less-glycated RBCs
Iron deficiency (untreated)	Falsely high	Older RBC population predominates
IV iron therapy / transfusions	Falsely low	Rapid RBC turnover
Carbamylated hemoglobin	Variable	Urea-derived carbamylation interferes with some assays
Metabolic acidosis	Variable	May alter hemoglobin-glucose binding kinetics
Hemoglobin variants	Variable	Assay-specific interference

The net effect is typically underestimation. HbA1c systematically underestimates true glycemia in HD patients by approximately 1.4 mmol/L (25 mg/dL) of mean glucose [6]. This is not a subtle bias — it is a clinically meaningful gap that can lead to false reassurance about glycemic control.

2.2 What the Guidelines Say — And Where They Diverge

A tension exists between KDIGO’s 2022 position and the emerging CGM-era evidence:

KDIGO 2022 Diabetes in CKD Guideline: Recommends HbA1c as the “primary glycemic biomarker” even in dialysis patients, with monitoring twice yearly for stable patients meeting goals and quarterly for those with therapy changes or unmet targets. KDIGO acknowledges that accuracy and precision decline in advanced CKD but argues that glycated albumin and fructosamine “offer no known advantages over HbA1c” and are biased by hypoalbuminemia [33].

ADA/KDIGO 2022 Consensus Report: Emphasizes concurrent use of CGM when HbA1c may be inaccurate or when assessing hypoglycemia risk. The consensus acknowledges that “neither glycated albumin nor fructosamine is without limitations” but stops short of replacing HbA1c as the primary marker [34].

2024 JDST Consensus on CGM in CKD: A more assertive position — recognizes that in patients with ESKD and “burnt-out diabetes,” CGM is superior to HbA1c for detecting occult hyperglycemia and hypoglycemia. Calls for greater CGM use in CKD and dialysis, while noting that CGMs are not FDA-approved for patients on dialysis [35].

Zelnick 2026 Diabetes Care (Prospective Study): The most recent and methodologically rigorous data. A prospective study using CGM in maintenance dialysis patients confirmed that both HbA1c and glycated albumin correlate strongly with CGM-derived mean glucose (r = 0.85 and 0.87, respectively), but each has substantial bias from clinical characteristics — HbA1c by ESA dose, hemoglobin, serum albumin, and BMI; glycated albumin by dialysis modality and vintage, residual kidney function, and BMI [36].

The bottom line: no single lab test is reliable in isolation. A multimodal approach is required.

2.3 The “Burnt-Out Diabetes” Phenomenon

Approximately 20% of diabetic ESKD patients have HbA1c values below 6.5% without antidiabetic therapy for more than 6 months — so-called “burnt-out diabetes” [9]. The 2024 Kaminski study in Diabetes Care used CGM (Dexcom G6) to evaluate these patients and demonstrated that:

Burnt-out diabetes patients actually have significantly higher mean daily glucose than non-diabetic ESKD controls
More frequent hyperglycemic episodes above 180 mg/dL
Greater glycemic variability (higher SD and mean amplitude of glycemic excursion)

The apparent “remission” is largely an artifact of HbA1c unreliability in ESKD. These patients are not in remission. They are undertreated.

Clinical Pearl

A “normal” HbA1c in a dialysis patient with a history of diabetes should not be reassuring. If you stop checking, you stop treating. The burnt-out diabetes literature demonstrates that the most dangerous glycemic patterns in dialysis — wide swings between hypo- and hyperglycemia — are invisible to HbA1c.

2.4 Alternative Glycemic Markers

Glycated Albumin (GA): - Reflects average glycemia over 2-3 weeks (albumin half-life approximately 20 days) - Unaffected by RBC lifespan, ESA use, or hemoglobin variants - Meta-analysis data demonstrate superior correlation with average glucose (pooled R = 0.57) compared to HbA1c (R = 0.49) in CKD stages 4-5 including dialysis [37] - Outperformed HbA1c and fructosamine against CGM in a small (n=40) burnt-out-diabetes study [9]; in the larger 2026 cohort, HbA1c and GA correlated similarly with CGM (r = 0.85 and 0.87) [36] - Limitation: Affected by conditions altering albumin metabolism — nephrotic syndrome, cirrhosis, peritoneal dialysis protein losses, severe malnutrition. The 2026 Zelnick study found GA biased by dialysis modality, vintage, residual kidney function, and BMI (serum albumin biased HbA1c, not GA) [36]

Fructosamine: - Measures glycation of all serum proteins (predominantly albumin) - Reflects glycemia over 2-3 weeks - Less specific than glycated albumin; affected by albumin levels and protein turnover - The 2024 Kaminski study found fructosamine was not superior to HbA1c for glycemic assessment in ESKD — a significant finding that has cooled enthusiasm for this marker [9]

Continuous Glucose Monitoring (CGM): - Gold standard for real-time glycemic assessment in HD patients - Captures glycemic variability, time in range (TIR), time above range (TAR), time below range (TBR), and hypoglycemic episodes that no single lab marker can detect - Dexcom G6/G7 and Libre 2/3 are used in dialysis, but device labeling states their use in dialysis has not been validated and they are not FDA-approved for this population [35] - Particularly valuable in detecting occult hyperglycemia in burnt-out diabetes - Increasingly incorporated into clinical practice; the 2024 JDST consensus report calls for greater CGM use in CKD, including dialysis [35] - Practical limitation: Insurance coverage remains inconsistent for dialysis patients not on intensive insulin therapy. Cost is a barrier.

2.5 Glycemic Targets in ESKD

KDIGO 2022 recommends an individualized HbA1c target, generally in the range of 6.5-8.0%, but acknowledges that HbA1c may not accurately reflect glycemia in this population. The ADA/KDIGO 2022 consensus suggests relaxing targets in patients at high risk of hypoglycemia, with limited life expectancy, or with significant comorbidities [33,34].

For CGM-based targets, the 2024 JDST consensus extrapolates the 2019 International Consensus targets for high-risk patients and notes they are not yet validated in CKD [35]:

CGM Metric	Target
Time in range (70-180 mg/dL)	> 50% (less stringent than general diabetes population)
Time below range (< 70 mg/dL)	< 1%
Time above range (> 180 mg/dL)	< 50%
Time above range (> 250 mg/dL)	< 10% [35]

Clinical Warning

KDIGO 2022 keeps HbA1c as the primary glycemic marker but states that its accuracy is low in dialysis, and it supports using CGM data when HbA1c does not match measured glucose or symptoms; it does not endorse glycated albumin or fructosamine as superior [33]. The ADA/KDIGO consensus favors adding CGM when HbA1c may be inaccurate [34]. In practice: do not act on HbA1c alone in a dialysis patient. The 2026 prospective data from Zelnick et al. show that glycated albumin also carries bias, which leaves CGM as the most direct glycemic tool in this population [35,36]. (Corrected 2026-09-26: an earlier version said KDIGO and ADA “prefer” a multimodal approach with glycated albumin, which contradicted §2.2.)

Section Summary

HbA1c systematically underestimates glycemia in HD patients due to shortened RBC lifespan, ESA use, and uremic effects — by approximately 25 mg/dL of mean glucose. Glycated albumin is an alternative that avoids red-cell bias, but it carries its own (dialysis modality, vintage, residual function, BMI) [36]; KDIGO 2022 does not endorse it as superior [33]. CGM is the most direct glycemic tool, capturing the glycemic variability and occult hyperglycemia that lab markers miss entirely. The “burnt-out diabetes” phenomenon is an artifact of HbA1c failure, not true remission. In practice: HbA1c remains KDIGO’s primary marker but should not be acted on alone — add CGM when it does not match glucose readings or symptoms, and use glycated albumin, if at all, as a trend marker with its biases in mind [33,34,36].

3. CKD-Mineral and Bone Disorder (CKD-MBD) Monitoring

3.1 KDIGO 2017 CKD-MBD Monitoring Recommendations

The KDIGO 2017 Guideline Update establishes the following monitoring schedule for CKD G5D patients [10]:

Parameter	Frequency in CKD G5D	Notes
Serum calcium	Every 1-3 months	More frequently if active vitamin D or calcimimetic therapy
Serum phosphorus	Every 1-3 months	Target: toward normal range; avoid persistent hyperphosphatemia
Intact PTH	Every 3-6 months	Trends more informative than single values
Alkaline phosphatase (ALP)	Every 12 months	More frequently if PTH elevated; marker of bone turnover
25(OH) Vitamin D	At initiation; repeat based on baseline and interventions	Correct deficiency per general population guidelines

A 2026 narrative review in BMC Nephrology comparing international guidelines (KDIGO, KDOQI, ERA-EDTA, CSN) found no true consensus on optimal testing frequency, though all guidelines agree on the core parameters. The variation lies in recommended intervals and target ranges [38].

3.2 PTH Targets and Interpretation

For patients on dialysis, KDIGO recommends maintaining PTH levels within approximately 2-9 times the upper limit of normal for the assay [10]. This is a wide range — deliberately so. The variability in skeletal responsiveness to PTH in ESKD is enormous, influenced by:

Duration of dialysis and prior parathyroid exposure
Degree of hyperphosphatemia and calcium-phosphorus product
Uremic toxin burden and chronic inflammation
Skeletal resistance to PTH (a hallmark of uremic osteodystrophy)
Vitamin D status and therapy

The 2023 KDIGO Controversies Conference (published 2025) acknowledged that PTH levels within this range represent a “gray zone” where standalone values are unreliable for predicting underlying bone histology. Bone biopsy remains the gold standard for diagnosing specific subtypes of renal osteodystrophy (high-turnover, low-turnover, mixed, osteomalacia), but it is rarely performed in clinical practice [11].

Clinical Pearl

Trends in PTH are more informative than individual values. A PTH of 600 pg/mL that has been stable for two years is a different clinical entity from a PTH of 600 pg/mL that was 200 pg/mL six months ago. Persistently rising PTH should prompt assessment for modifiable causes (vitamin D deficiency, hyperphosphatemia, inadequate dialysis, medication non-adherence) and consideration of medical therapy escalation — calcimimetics, active vitamin D, or ultimately surgical parathyroidectomy.

3.3 Phosphorus Management: The Evidence Gap

Hyperphosphatemia is associated with vascular calcification, cardiovascular events, and mortality in observational studies. The association is robust and consistent across cohorts. What is less clear is whether lowering phosphorus — particularly with phosphate binders — improves outcomes. No placebo-controlled randomized trial has demonstrated that phosphate binder therapy reduces mortality in dialysis patients. The KDIGO 2017 guideline recommends lowering elevated phosphorus “toward the normal range” (2C) while acknowledging the limited interventional evidence [10].

3.4 Vitamin D

Vitamin D deficiency is nearly universal in ESKD. KDIGO suggests that 25(OH) vitamin D might be measured, with repeat testing guided by baseline values and interventions, and that deficiency be corrected using general-population strategies (2C). Whether nutritional vitamin D supplementation (cholecalciferol or ergocalciferol) improves clinical outcomes in dialysis beyond correcting the lab value remains uncertain [10].

Active vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) are used to manage secondary hyperparathyroidism. Their role in bone and cardiovascular outcomes continues to be debated.

Section Summary

CKD-MBD monitoring in HD patients follows KDIGO 2017 guidelines: calcium and phosphorus every 1-3 months, PTH every 3-6 months, ALP annually, and vitamin D at initiation. PTH should be maintained at 2-9 times the upper limit of normal, but trends matter far more than individual values. No placebo-controlled RCT has shown that phosphate binder therapy reduces mortality. The 2023 KDIGO Controversies Conference (published 2025) reinforced that bone biopsy remains the only definitive diagnostic tool for renal osteodystrophy subtypes, but clinical management is guided by biochemical trends in the vast majority of patients.

4. Hepatitis B and C Screening

4.1 Hepatitis C Virus (HCV)

HD patients are at increased risk of HCV acquisition through nosocomial transmission in dialysis units. About 7% of chronic HD patients in the US are HCV seropositive (7.3% in DOPPS 5, 2012), though rates have declined with improved infection control and universal precautions [12].

KDIGO 2022 Clinical Practice Guideline for Hepatitis C in CKD [12] (recommendation numbers from the guideline’s Chapter 1; verified against the full KDIGO text 2026-09-26):

Recommendation	Grade
Screen all patients for HCV at initial CKD evaluation (1.1.1)	1C
Screen at HD initiation or upon transfer from another facility (1.1.2) — NAT alone, or immunoassay followed by NAT if positive (1.1.2.1)	1A
Ongoing screening: immunoassay or NAT every 6 months for in-center HD patients (1.2.1)	1B
New HCV infection in the unit: test all patients and increase testing frequency (1.2.1.2)	1A
Serum ALT: check at HD initiation or transfer (1.2.2, 2B), then monthly in HD patients (1.2.2.1)	2B
Resolved HCV: repeat NAT every 6 months to detect reinfection (1.2.1.3)	1B

CMS incorporates the CDC 2001 hemodialysis recommendations by reference but excludes their hepatitis C screening provisions [124]; the every-6-month schedule is guideline practice (KDIGO 2022 [12]; CDC 2001: anti-HCV semiannually, ALT monthly [113]), not a Conditions for Coverage requirement.

The advent of direct-acting antivirals (DAAs) has transformed HCV management in CKD. Glecaprevir/pibrentasvir (Mavyret) is approved for all CKD stages including dialysis and achieves sustained virologic response (SVR) rates of approximately 97% in dialysis populations (KDIGO pooled SVR12 96.9% across 11 studies) [12]. KDIGO recommends DAA therapy for every transplant candidate with HCV, before or after transplantation, timed with the transplant center (1A), and recommends that kidneys from HCV-infected donors be considered regardless of the recipient’s HCV status (1C) [12].

Clinical Pearl

HCV screening in dialysis is not merely an infection control measure. It is a transplant planning tool. An undiagnosed HCV infection delays waitlisting, complicates donor matching, and impairs post-transplant outcomes. The screening interval — every 6 months — should be considered a minimum, with more frequent testing during outbreak investigations.

4.2 Hepatitis B Virus (HBV)

HD patients have impaired humoral and cellular immune responses to HBV vaccination, making both screening and vaccination critical components of health maintenance.

CDC recommendations — 2001 dialysis infection-control guidance [113] and 2023 universal triple-panel screening [13]:

Action	Details
Screen at HD initiation	Triple panel: HBsAg, anti-HBs, total anti-HBc
Annual anti-HBs monitoring	In vaccinated HD patients
Revaccinate	If anti-HBs falls below 10 mIU/mL
Segregate HBsAg-positive patients	Dedicated machines; staff should not simultaneously care for HBV+ and HBV-susceptible patients
Vaccination strategy	High-dose formulations recommended

Vaccine considerations in dialysis:

Standard-dose hepatitis B vaccine produces adequate antibody responses far less often in dialysis patients than in the general population. High-dose formulations are recommended [113]:

Recombivax HB 40 mcg (the dialysis formulation, four times the 10-mcg adult dose) on a 0-, 1-, 6-month schedule — the traditional HD-specific regimen [113,125]
Engerix-B 40 mcg (two 20-mcg doses) on a 0-, 1-, 2-, 6-month schedule — the CDC alternative for adults on hemodialysis [113,117]
Heplisav-B (HBsAg with CpG 1018 adjuvant) — achieves higher seroprotection rates in the general population, but safety and effectiveness have not been established in adults on hemodialysis per the package insert and CDC [117]
PreHevbrio (three-antigen vaccine) — no longer available in the US; voluntary nationwide recall of remaining supply, November 2024 [117]
Nonresponders to the initial series should receive a second complete 3-dose series

Clinical Warning

Anti-HBs titers decline faster in dialysis patients than in the general population. Annual monitoring is not optional — it is the mechanism by which waning immunity is detected before a nosocomial exposure occurs. Revaccination when titers fall below 10 mIU/mL is standard practice [113].

Section Summary

Hepatitis screening in HD serves dual purposes — infection control and transplant planning. HCV screening every 6 months by immunoassay or NAT is KDIGO 1B, with DAA therapy now achieving approximately 97% SVR even in ESKD [12]. HBV screening at initiation with annual anti-HBs monitoring is essential given the impaired vaccine response in dialysis patients, who reach adequate antibody levels with standard dosing far less often than the general population [113]. High-dose hepatitis B vaccine formulations are recommended, and annual monitoring with revaccination at titers below 10 mIU/mL is the standard.

5. Thyroid Screening

5.1 Prevalence and Clinical Significance

Hypothyroidism is significantly more prevalent in ESKD than in the general population. Reported rates range from 11% to 20% depending on the TSH threshold and population studied [14-17]:

Study	Population	Prevalence	Definition
FHN Trial (Lo 2017) [16]	226 HD patients	11%	TSH >= 8 mIU/mL or on thyroid hormone
HCS cohort (Rhee 2017) [15]	541 HD patients	Highest TSH tertile: 2.2- to 2.5-fold mortality	TSH tertiles (not a prevalence study)
Cuna 2017 [14]	2,147 ESKD transplant-waitlist patients (Italy)	20.3% (two-thirds subclinical)	TSH > 3 mU/L
2025 Nature Reviews (Brenta) [39]	Narrative review	Subclinical hypothyroidism more common in CKD than in the general population	Variable thresholds

A 2025 comprehensive review in Nature Reviews Endocrinology synthesized the relationship between kidney diseases and thyroid function, confirming that hypothyroidism in ESKD is not merely a laboratory curiosity [39]. Higher TSH levels are independently associated with:

Coronary artery calcification in HD patients [17]
Increased mortality — the highest vs lowest TSH tertile carried 2.2- to 2.5-fold mortality in a prospective HD cohort [15]; thyroid hormone resistance tracked all-cause and CV mortality in CKD [40]
Left ventricular hypertrophy and diastolic dysfunction — exacerbating the already-prevalent cardiac structural disease in ESKD

5.2 Diagnostic Challenges

The symptoms of hypothyroidism overlap extensively with uremia — fatigue, cold intolerance, edema, constipation, dry skin, cognitive impairment, and weight gain are common to both conditions. Clinical diagnosis alone is unreliable. The diagnosis must be biochemical.

Low T3 syndrome (euthyroid sick syndrome) is common in ESKD and does not require treatment. It results from impaired peripheral conversion of T4 to T3, decreased TBG levels, and the catabolic/inflammatory milieu of chronic kidney disease. Low T3 is associated with worse outcomes in observational studies, but treatment trials have not demonstrated benefit — and thyroid hormone supplementation carries risk of atrial fibrillation and accelerated bone loss [39].

Clinical Pearl

Diagnose hypothyroidism in ESKD based on persistently elevated TSH, not FT3 or FT4 alone. Free hormone assays are unreliable in uremia due to protein-binding abnormalities, assay interference from uremic toxins, and the confounding effect of non-thyroidal illness. A TSH above the upper limit of normal on two consecutive measurements — not a single value — should trigger evaluation and consideration of levothyroxine therapy.

5.3 Thyroid Cancer Risk

An additional consideration: ESKD patients have a higher reported incidence of benign and malignant thyroid nodules [14], though the absolute risk of thyroid cancer remains low. KDIGO does not issue a formal thyroid cancer screening recommendation. Clinical vigilance — thyroid palpation during routine exams, with ultrasonography if nodules are detected — is a reasonable approach [14,39].

5.4 Screening Recommendations

No formal guideline mandates thyroid screening in HD. However, given the high prevalence (11-20% [14], [16]), extensive symptom overlap with uremia (making clinical diagnosis impossible), and association with cardiovascular morbidity and mortality:

Recommended approach: - TSH at HD initiation — baseline assessment - TSH annually — surveillance - FT4 confirmation if TSH is abnormal - Do not check FT3 routinely — it is unreliable in ESKD and low T3 syndrome is common

Section Summary

Hypothyroidism affects 11-20% of HD and transplant-waitlisted ESKD patients [14], [16] — higher than in the general population. Its symptoms are indistinguishable from uremia, making clinical diagnosis impossible and laboratory screening essential. TSH is the most reliable test; FT3 and FT4 assays are unreliable in uremia. Higher TSH is independently associated with coronary calcification and mortality. TSH screening at HD initiation and annually thereafter is reasonable. Low T3 syndrome is common, associated with worse outcomes, but does not require treatment.

6. Cancer Screening: General Principles

6.1 The Screening Dilemma

Cancer screening guidelines were developed for populations with decades of remaining life expectancy. The median survival of incident HD patients in the US is approximately 3-5 years (5-year survival approximately 40% [29]), with wide heterogeneity based on age, diabetes status, comorbidities, and functional status. For a screening test to provide benefit, the lead time from detection to mortality reduction must fall within the patient’s expected survival window — typically 5-10 years for most cancers [18,19].

The ASN Choosing Wisely campaign explicitly recommends: “Don’t perform routine cancer screening for dialysis patients with limited life expectancies without signs or symptoms” [18].

A 2024 CJASN review — “Cancer Screening Among Patients with Kidney Failure Requiring Hemodialysis: Where We Are and Where We Are Going” — provides the most current framework for this decision space. The review highlights that general population screening guidelines are not directing care in HD, and nephrologists are increasingly wrestling with ownership of preventive care decisions in a population for whom those guidelines were never designed [20].

6.2 Individualized Framework

Factor	Implication
Expected survival > 5-10 years	May benefit from standard screening
Transplant candidacy	Should receive age-appropriate screening per general population guidelines
Patient goals and values	Shared decision-making essential — burden vs. benefit
Functional status	Patients with good functional status on dialysis may have better-than-average survival
Not transplant-eligible, survival < 5 years	Screening likely causes net harm (false positives, procedures, anxiety)

6.3 Cancer-Specific Considerations

Colorectal Cancer: - Frequently screened: 11.6% of Medicare dialysis patients aged 50 or older had a colorectal screening test over a median 1.5 years [19] - Screening-test performance differs in dialysis [49]; guaiac-based fecal occult blood testing is prone to false positives from uremic platelet dysfunction and heparin exposure, so fecal immunochemical testing (FIT) is preferred - Colonoscopy bowel prep can cause electrolyte disturbances, dehydration, and hemodynamic instability - Modeling study: CRC screening adds only 2.6 days of life for non-waitlisted dialysis patients vs. 12 days for transplant recipients [42] - In a large USRDS cohort (469,574 patients), screening was appropriately targeted toward lower-risk patients but absolute rates suggested overscreening in some groups [19]

Prostate Cancer: - PSA levels are frequently elevated in dialysis patients independent of malignancy, reducing specificity - No dialysis-specific PSA screening guideline exists - Individualize based on transplant candidacy and expected survival

Breast Cancer: - Mammographic interpretation may be complicated by vascular and metastatic soft tissue calcifications - Standard screening for transplant candidates with adequate expected survival - No dialysis-specific modification recommended

Cervical Cancer: - Standard screening guidelines apply for transplant candidates - Limited data on cervical cancer risk specific to ESKD

Clinical Warning

Overscreening in dialysis carries real harms: false-positive results leading to invasive procedures in patients with uremic platelet dysfunction and vascular access that limits venipuncture sites; bowel preps that destabilize electrolytes and volume status; and anxiety about findings that would never have become clinically significant within the patient’s remaining lifespan [18-20].

Section Summary

Cancer screening in HD patients must be individualized based on transplant candidacy, expected survival, and patient goals. The ASN Choosing Wisely campaign recommends against routine screening in patients with limited life expectancy [18]. Transplant candidates should receive standard age-appropriate screening. For non-candidates with less than 5-year expected survival, the harms of screening — false positives, procedural complications, anxiety — likely outweigh the minimal mortality benefit. FIT is preferred over guaiac-based FOBT. Guaiac FOBT and mammography have reduced specificity in ESKD due to uremic platelet dysfunction and vascular calcifications, respectively; PSA specificity is also reduced [49].

7. Renal Cell Carcinoma Screening in ESKD: Acquired Cystic Kidney Disease

7.1 Acquired Cystic Kidney Disease (ACKD) — Epidemiology

ACKD is one of the most underrecognized complications of long-term dialysis. Defined as the development of three or more cysts in each kidney in a patient with CKD and no history of hereditary cystic disease, its prevalence increases dramatically with dialysis duration [21,22]:

Duration on Dialysis	ACKD Prevalence [21]
< 3 years	10-20%
3-5 years	40-60%
> 10 years	> 90%

A 2025 systematic review and meta-analysis in the World Journal of Surgical Oncology confirmed a standardized incidence ratio (SIR) of 4.7 for kidney and renal pelvis cancer in dialysis patients compared to the general population [24]. This is not a theoretical risk. It is a measurable, dose-dependent complication of dialysis duration.

7.2 Risk of Renal Cell Carcinoma

ACKD carries a markedly elevated risk of renal neoplasia [21-24]:

RCC risk is up to 50-fold higher than the general population [21]
Overall incidence of ACKD-associated RCC: 3-7% of ESKD native kidneys
ACKD-RCC is the most common RCC subtype in both ACKD (40%) and ESKD (30%) — recognized as a distinct entity in the 2022 WHO Classification of Renal Tumors
Tumors are frequently multifocal (approximately 50%) and bilateral (approximately 9%) [21]
Occurs approximately 20 years earlier than sporadic RCC
Predominantly affects males (3:1 male-to-female ratio)
Frequently asymptomatic (approximately 86%) [21]; symptoms when present include hematuria, flank pain, or abrupt unexplained hematocrit changes

7.3 Pathogenesis

The 2022 WHO Classification recognizes ACKD-RCC as a distinct renal tumor subtype. The pathogenesis involves a chronic multifactorial milieu [21,43]:

Uremic toxin exposure and impaired cellular immunity
Oxidative stress and reactive oxygen species generation
Oxalate crystal-induced chronic tubular injury
Growth factor-driven compensatory tubular epithelial proliferation
Potential proto-oncogene activation in the setting of chronic cellular turnover

The progression follows a stepwise pathway: damaged renal tubule -> simple cyst -> cyst with atypical epithelial lining -> adenoma -> carcinoma. This stepwise model supports the rationale for surveillance — there is a detectable premalignant phase [21].

7.4 Histologic Features

ACKD-RCC has characteristic features distinguishing it from other RCC subtypes [43]:

Predominantly eosinophilic cells with granular cytoplasm
Variable cribriform (“sieve-like”), solid, and papillary architecture
Intratumoral oxalate crystals — characteristic but not required for diagnosis
Background cystic renal parenchyma
CAIX negative (vs. positive in clear cell RCC)
CK7 usually negative (vs. positive in papillary RCC)
Overall indolent behavior, though 10-15% present with recurrence or distant metastases

7.5 Screening Recommendations

There is no universal guideline for RCC screening in dialysis patients. The KDIGO 2020 Transplant Candidate guideline recommends ultrasonographic screening for renal cell carcinoma in patients at increased risk — including those with >= 3 years on dialysis, family history of renal cancer, ACKD, or analgesic nephropathy [44]. For the general (non-transplant-candidate) dialysis population, an individualized approach is recommended.

Suggested screening protocol:

Dialysis Duration	Recommendation	Rationale
Years 0-3	No routine imaging (unless symptomatic)	ACKD prevalence low; risk-benefit unfavorable
Year 3	Baseline renal ultrasound	Assess for ACKD; prevalence 40-60% at this point [21]
Years 3-5	Repeat ultrasound every 1-2 years if ACKD present	Monitor for solid lesions
After 5+ years	Annual renal ultrasound if ACKD established	Highest risk period; prevalence > 90% after 10 years [21]
Transplant candidates	Pre-transplant imaging of native kidneys; continued post-transplant surveillance	ACKD and RCC risk persist in native kidneys after transplant

Imaging modality selection:

Modality	Role	Notes
Renal ultrasound	First-line screening	Detects cysts and solid masses; operator-dependent; may miss small tumors in severely cystic kidneys
CT with contrast	Definitive characterization	Superior sensitivity; no nephrotoxicity concern in dialysis-dependent patients; use for suspicious US findings
MRI	Alternative to CT	Gadolinium is acceptable in established dialysis patients with post-dialysis removal; avoid in pre-dialysis CKD (NSF risk)

Management of detected lesions:

Finding	Approach
Tumor > 3 cm	Nephrectomy recommended
Tumor < 3 cm with symptoms	Consider nephrectomy
Tumor < 3 cm, asymptomatic	Serial imaging; growth rate guides intervention
Post-transplant native kidneys	Continue surveillance — ACKD-RCC risk persists

Clinical Pearl

ACKD-RCC accounts for approximately 2% of deaths in kidney transplant patients [21]. Native kidney surveillance should not stop after transplantation. Young patients on long-term dialysis represent the highest-risk group and derive the greatest benefit from screening [21,22,24].

Clinical Warning

Large tumors (up to 8 cm) have been reported that were not visualized by any imaging modality in extensively cystic ACKD kidneys. The altered architecture makes radiologic interpretation challenging — have a low threshold for CT characterization of any new or changing finding on ultrasound [21].

Section Summary

ACKD develops in over 90% of patients on dialysis for more than 10 years and carries up to a 50-fold increased RCC risk [21]. The 2022 WHO Classification recognizes ACKD-RCC as a distinct tumor subtype. Ultrasound screening should begin at 3 years of dialysis — the inflection point where ACKD prevalence rises sharply — with annual surveillance thereafter. CT with contrast is the definitive characterization tool (no nephrotoxicity concern in dialysis-dependent patients). This is a critically underrecognized screening opportunity: the premalignant phase is detectable, the tumors are frequently asymptomatic, and early intervention changes outcomes.

8. Other Screening Considerations

8.1 Anemia Monitoring

Updated 2026-09-26 to KDIGO 2026

This section was written against KDIGO 2012 [45], which the KDIGO 2026 Anemia in CKD guideline superseded in January 2026 [101,102]. Changed: guideline citation; ESA initiation and upper target; iron initiation, withholding thresholds, and proactive dosing; iron-study frequency; the trial populations behind the hemoglobin ceiling; HIF-PHI positioning.

Anemia is universal in ESKD and requires structured monitoring to guide ESA and iron therapy. The KDIGO 2026 Anemia Guideline provides the framework [101,102]:

Monitoring schedule:

Parameter	Frequency	Clinical Use
CBC (hemoglobin)	At least monthly in HD patients on ESA therapy	Guide ESA dose adjustments; start ESA at Hb ≤9.0-10.0 g/dL (2D); target below 11.5 g/dL (1D) [101]. The US epoetin label is stricter — reduce or interrupt as Hb approaches or exceeds 11 g/dL [109]
Iron studies (ferritin, TSAT)	Every 1-3 months in HD [101]	Guide IV iron therapy; initiate iron at ferritin ≤500 ng/mL and TSAT ≤30% (2D); reasonable to withhold routine iron at ferritin >700 ng/mL or TSAT ≥40% [101]
Reticulocyte hemoglobin content (CHr/Ret-He)	As needed	Detect functional iron deficiency; CHr < 29 pg suggests iron-restricted erythropoiesis even with adequate stores. Cutoffs circulate (Fishbane’s validation used < 26 pg [110]); KDIGO 2026 did not adopt CHr
Reticulocyte count	As needed	Assess erythropoietic response to ESA; rising reticulocytes indicate ESA responsiveness

Key principles: - ESA hyporesponsiveness (failure to achieve target Hb despite adequate ESA dosing) should prompt evaluation for iron deficiency, inflammation, occult blood loss (GI), hyperparathyroidism, B12/folate deficiency, hemoglobinopathy, or malignancy — not reflexive dose escalation - IV iron is preferred over oral iron in HD patients due to poor GI absorption and convenience of administration during dialysis sessions (KDIGO 2026, 2D) [101] - Proactive IV iron to maintain stable iron status is now a KDIGO practice point for HD [101]. PIVOTAL (n=2,141 incident HD patients, academic-funded): death, MI, stroke, or HF hospitalization 29.3% proactive vs 32.3% reactive — ARR 3.0% | NNT 34 over a median 2.1 years — with less ESA use and no increase in infection [107,108] - Upper hemoglobin limit: KDIGO 2026 recommends targeting Hb below 11.5 g/dL (1D), replacing the 2012 “do not intentionally exceed 13 g/dL (1A)” [101]. The hemodialysis-population trials behind this ceiling are the Normal Hematocrit Trial (HD patients with heart disease; halted early; the FDA-filed report showed death RR 1.27, 95% CI 1.04–1.54) and Parfrey 2005 (incident HD; no LV benefit, more cerebrovascular events) [103,104,105]. CHOIR, CREATE, and TREAT enrolled non-dialysis CKD [82,83,84]: CHOIR raised the composite of death, MI, CHF hospitalization, and stroke (HR 1.34) [82]; CREATE showed no difference in cardiovascular events [83]; TREAT doubled stroke (HR 1.92) [84]. None showed a statistically significant mortality increase on its own — the mortality signal is meta-analytic (RR 1.17 across nine target trials) [106] - HIF-PH inhibitors: KDIGO 2026 suggests an ESA rather than a HIF-PHI first-line (2D) [101]. As of September 2026, vadadustat (Vafseo) is the only HIF-PHI marketed in the US for dialysis patients [111]

Clinical Pearl

A ferritin above 500 ng/mL does not necessarily mean iron overload in a dialysis patient — ferritin is an acute-phase reactant elevated by inflammation. Conversely, a normal ferritin with a low TSAT indicates functional iron deficiency. The TSAT is the more actionable number in guiding iron therapy decisions.

8.2 Nutritional Assessment

Protein-energy wasting (PEW) affects 28-54% of maintenance dialysis patients (interquartile range across 90 studies) [114] and is independently associated with increased morbidity and mortality. A 2024 systematic review and meta-analysis in Clinical Nutrition demonstrated a pooled mortality hazard ratio of 1.49 (95% CI: 1.36-1.64) for malnourished dialysis patients across 29 cohort studies — the kind of effect size that should drive routine screening [46].

Monitoring parameters:

Parameter	Frequency	Significance
Serum albumin	Monthly	Inflammation + nutritional marker; < 3.5 g/dL associated with increased mortality. Not purely nutritional — acute inflammation drives albumin down independently of nutritional status
Prealbumin (transthyretin)	As indicated	Shorter half-life (2 days) may reflect more recent nutritional intake; less standardized
Subjective Global Assessment (SGA)	Nutrition screening at least every 6 months; RDN comprehensive assessment within 90 days of starting dialysis, then annually or as indicated [116]	Validated composite tool incorporating weight change, dietary intake, GI symptoms, functional capacity, physical examination
nPNA (normalized protein nitrogen appearance)	Monthly	Complementary marker of protein intake, not to be read in isolation; KDOQI 2020 sets dietary protein at 1.0-1.2 g/kg/day and gives nPCR no separate target [116]
BMI and body composition	At initiation; periodically	Interpretation complex — “obesity paradox” in dialysis; higher BMI associated with better survival in observational data

International Society of Renal Nutrition and Metabolism (ISRNM) criteria for PEW diagnosis [112]: Requires at least one criterion in three of four categories: 1. Low serum chemistry (albumin < 3.8 g/dL, prealbumin < 30 mg/dL, cholesterol < 100 mg/dL) 2. Low body mass (BMI < 23, unintentional weight loss > 5% over 3 months or > 10% over 6 months, total body fat < 10%) [112] 3. Reduced muscle mass (muscle wasting of 5% over 3 months or 10% over 6 months; mid-arm muscle circumference > 10% below the 50th percentile of a reference population; low creatinine appearance) [112] 4. Low dietary intake (protein < 0.8 g/kg/day or energy < 25 kcal/kg/day for > 2 months)

Clinical Warning

Serum albumin below 3.5 g/dL in a dialysis patient is a red flag — but the reflex to attribute it purely to malnutrition is wrong. Inflammation (elevated CRP, IL-6) drives albumin down through increased catabolism and decreased hepatic synthesis. Treating the “low albumin” with nutritional supplementation alone while ignoring the inflammatory driver misses the pathophysiology.

8.3 Cardiovascular Screening

Cardiovascular disease accounts for the majority of deaths in ESKD patients. Structured cardiovascular assessment includes:

Echocardiography: - At HD initiation — baseline assessment of LV function, chamber dimensions, valvular calcification, and pericardial disease - Every 1-3 years — surveillance for progressive LV hypertrophy (present in most HD patients), diastolic dysfunction, and valvular calcification - After volume optimization — echocardiography performed on the day after dialysis (when closest to “dry weight”) provides the most accurate assessment of LV function - Key findings to monitor: LV mass index, ejection fraction, mitral/aortic valve calcification, pericardial effusion, RV systolic pressure (pulmonary hypertension screen)

ECG: - At initiation and periodically - Primary role: detect electrolyte-driven arrhythmias (hyperkalemia, hypocalcemia), QTc prolongation, and conduction abnormalities - HD patients are at high risk of sudden cardiac death — the leading cause of cardiovascular mortality in ESKD — driven by rapid electrolyte shifts during and immediately post-dialysis

Stress testing: - For transplant candidacy evaluation per institutional protocols - Not routinely recommended for asymptomatic HD patients who are not transplant candidates - The diagnostic accuracy of stress testing is reduced in ESKD due to high prevalence of LVH, baseline ECG abnormalities, and chronotropic incompetence

Clinical Pearl

Pulmonary hypertension in ESKD is common (20-60% of HD patients in recent cohorts, depending on the study and definition [55]) and independently associated with increased mortality. Echocardiographic screening detects elevated RV systolic pressure, but most PH in dialysis is postcapillary (group 2 — related to volume overload and left heart disease). AV fistula flow can also contribute. Management focuses on volume optimization and AV access assessment before considering PH-specific therapies.

8.3.1 Right Heart Assessment and Access-Related High-Output Cardiac Failure

Every arteriovenous fistula is a left-to-right shunt. The hemodynamic cost is real: increased venous return, increased preload, increased cardiac output, and — over months to years — progressive biventricular remodeling. This is not a rare complication — in one single-center cohort, 29.4% (10 of 34) of AVF patients who underwent right heart catheterization met HOHF criteria [65]. It is a predictable physiologic consequence of the access itself, and it is underrecognized and underreported [52,53].

The hemodynamic burden of AV access

A functioning AV fistula diverts 400–2,000+ mL/min of arterial blood directly into the venous circulation, bypassing the capillary bed entirely. The heart must increase its output to maintain systemic perfusion — the “effective cardiac output” (total CO minus access flow) is what actually perfuses the organs [54]. When access flow exceeds 1.5–2.0 L/min or consumes more than 25–30% of cardiac output, the hemodynamic burden crosses from compensated into pathologic territory [55].

The consequences are progressive and predictable:

Hemodynamic Change	Mechanism	Clinical Consequence
Increased venous return	Direct arteriovenous shunting	RV volume overload, elevated RA pressure
Increased cardiac output	Frank-Starling compensation for shunted volume	LV eccentric hypertrophy, high-output state
Decreased systemic vascular resistance	Baroreceptor-mediated vasodilation	Wide pulse pressure, bounding pulses
Elevated pulmonary artery pressure	Increased RV preload transmitted to pulmonary vasculature	Pulmonary hypertension (precapillary component)
RV dilation and dysfunction	Chronic volume overload exceeding RV compliance	Right heart failure, hepatic congestion, ascites

The right heart is the weak link. The RV is a thin-walled, compliant chamber designed for a low-pressure circulation. Chronic volume overload from high-flow AV access forces the RV to operate as a volume pump at pressures it was never designed to sustain. The result is progressive RV dilation, tricuspid regurgitation (from annular dilation), elevated right atrial pressure, hepatic congestion, and — in severe cases — refractory ascites that can masquerade as dialysis-related fluid overload [56].

High cardiac output as a mortality driver

High-output heart failure (HOHF) from AV access is not merely a hemodynamic curiosity. It carries real mortality risk. Reddy et al. (2017) demonstrated in a retrospective echocardiographic study (n=137, median 2.6 years after access creation) that RV dilation following AVF/AVG creation is independently associated with increased mortality — HR 3.9 (95% CI 1.7–9.2) [62]. RV end-diastolic volume index increased significantly within 8 months of AVF creation (80 ± 15 to 91 ± 18 mL/m²), with RV changes driven by volume overload and elevated LV filling pressures [63]. The cardiac remodeling — LV hypertrophy, diastolic dysfunction, progressive RV failure — contributes to the cardiovascular mortality that dominates outcomes in ESKD. A 2025 narrative review synthesizing evidence from 2018–2025 confirmed that access flows exceeding 1.5–2.0 L/min or consuming >25–30% of cardiac output are strongly associated with LVH, HOHF, and pulmonary hypertension [55]. Basile et al. found that a Qa/CO ratio ≥20% had 100% sensitivity and 74.7% specificity for high-output cardiac failure, and Qa ≥2.0 L/min 89% sensitivity and 100% specificity [67]; a 2025 prospective study found a baseline Qa of approximately 1.4 L/min identified patients with Qa/CO >0.3 (AUC 0.97) [64].

The clinical signals are often misattributed:

Dyspnea attributed to volume overload or anemia — when the cause is high cardiac output and elevated pulmonary pressures from the fistula
Peripheral edema attributed to missed ultrafiltration targets — when it reflects right heart failure from chronic RV volume overload
Ascites attributed to liver disease or peritoneal pathology — when it is hepatic congestion from RV failure driven by high-flow access [56]
Hypotension during dialysis attributed to ultrafiltration rate — when high-flow access creates coronary steal, particularly in patients with prior CABG using internal mammary artery grafts [57]

Echocardiographic assessment: what to look for

The standard echocardiographic screening for HD patients (Section 8.3 above) should be expanded to include a structured right heart assessment. The following parameters should be measured at baseline and at each surveillance echo:

Parameter	What It Tells You	Threshold for Concern
RV basal diameter	RV volume overload	>41 mm (dilated)
TAPSE (tricuspid annular plane systolic excursion)	RV systolic function	<17 mm (reduced)
RV S’ (tissue Doppler)	RV longitudinal function	<9.5 cm/s
RVSP (from TR jet velocity)	Pulmonary artery pressure	>35 mmHg (elevated); >50 mmHg (severe)
TR severity	RV/annular dilation consequence	Moderate or greater = investigate access flow
RA area	RV filling pressure	>18 cm²
E/e’ ratio	LV diastolic function / filling pressure	>14 (elevated)
Cardiac output (LVOT VTI × LVOT area × HR)	Total cardiac output	>7 L/min warrants access flow measurement
Height-indexed Qa (access flow / height^2.7)	Body-size-adjusted access flow burden	≥603 mL/min/m^2.7 (100% sensitivity, 60% specificity for HOHF in 29 patients with Qa ≥2,000 mL/min) [66]
IVC diameter and collapsibility	Volume status and RA pressure	Dilated (>21 mm) with <50% collapse = elevated RA pressure

Pre-access echocardiography should be standard. Before any access creation — fistula, graft, or catheter — a baseline echocardiogram should assess biventricular function, chamber dimensions, RVSP, and diastolic parameters. This is not optional in patients with any cardiac history. The echocardiographic findings directly inform which access type to create, whether to pursue forearm-first vs upper arm, and whether shunt physiology is safe at all. A patient with pre-existing RV dilation and RVSP >40 mmHg who receives an upper arm AVF is being set up for cardiac decompensation — and no amount of post-hoc monitoring will undo a hemodynamic insult that should have been anticipated.

When echocardiography reveals elevated RVSP, RV dilation, or unexpectedly high cardiac output, the next step is to measure access flow — typically by ultrasound dilution or duplex ultrasound during dialysis. The critical relationship is the Qa/CO ratio: the proportion of total cardiac output consumed by the access. A Qa/CO ratio exceeding 25–30% identifies patients at high risk for progressive cardiac remodeling [55], [64].

Clinical Pearl

The occlusion test is a simple bedside maneuver that can unmask access-related HOHF. Temporarily compress the fistula (manual or blood pressure cuff proximal to the anastomosis) and observe the hemodynamic response. A drop in heart rate (Branham sign — a vagally mediated reflex) and improvement in blood pressure confirm that the access is driving the high-output state. Resolution of elevated RVSP on echo during fistula occlusion — as demonstrated by Hartley et al. (2020) in a patient with 3 L/min fistula flow — proves reversibility and supports intervention [59].

Vascular access selection: when the fistula is the wrong answer

The “fistula first” paradigm — enshrined in KDOQI 2006 and the CMS Fistula First Breakthrough Initiative — transformed vascular access practice and reduced catheter-related complications for millions of patients. But it was never intended to be fistula-only, and the paradigm has evolved. The 2019 KDOQI Vascular Access Update and the 2024 Lok JAMA review both emphasize individualized access planning using a Patient Life-Plan (P-L-A-N) framework that accounts for cardiac comorbidity, life expectancy, vessel mapping, and patient preference [52,53].

For patients with pre-existing cardiac disease — particularly those with reduced ejection fraction, RV dysfunction, or established pulmonary hypertension — the hemodynamic burden of a high-flow upper arm fistula may outweigh the infection and patency advantages. The evidence supports a tiered approach to access selection based on cardiac status:

Cardiac Status	Preferred Access Strategy	Rationale
Normal LV/RV function, EF >50%	Standard AVF (forearm preferred → upper arm)	Full hemodynamic reserve; tolerate access flow
Reduced EF (35–50%) or mild RV dilation	Forearm AVF (radiocephalic) preferred over upper arm	Forearm AVF mean flow approximately 948 mL/min vs 1,580 mL/min for upper arm [67]; 64% lower risk of hand-ischemia interventions [68]; lower Qa/CO ratio; less cardiac remodeling
EF <35%, moderate-severe RV dysfunction, or established HOHF	Forearm AVG or catheter; avoid upper arm AVF	AV graft flow is more predictable and typically lower (600–1,000 mL/min); graft can be banded more easily; catheter avoids shunt physiology entirely
Severe cardiomyopathy, NYHA III-IV, or prior AVF-related HOHF	Tunneled catheter or forearm graft with flow restriction	In patients with symptomatic heart disease, CVC demonstrated non-inferior major adverse event-free survival vs AVF; more AVF patients deteriorated in HF status (35/57 vs 10/42) [69]. KDOQI 2019 specifically identifies EF <15% as an indication for long-term catheter use
Post-transplant with functioning fistula	Evaluate for ligation	25.7% of transplant recipients with prior AVF required ligation for cardiac failure symptoms; mean flow in the intervention group was 2,197 mL/min vs 851 mL/min in non-intervention [60]

The Fisher et al. (2024) data complicate this picture in an important way: among patients with established heart failure, AVG had dramatically worse patency than AVF — primary-assisted patency 39% vs 87% at one year (p < 0.0001) [61]. This means the graft option, while hemodynamically safer, trades cardiac risk for access failure risk. The clinical decision is not which access type is “better” — it is which failure mode the patient can least afford.

Clinical Warning

Upper arm fistulas carry the highest hemodynamic risk. Upper arm access carries an OR of 8.1 (95% CI 1.8–35.7) for a high Qa/CO ratio (>0.3) compared to forearm access [64]. The brachial artery delivers 3–5x the flow of the radial artery. Upper arm (brachiocephalic and brachiobasilic) fistulas are disproportionately represented in HOHF cases and in post-transplant fistula ligation cohorts (41.7% of closures were upper arm AVF) [60]. Forearm AVFs have 64% lower risk of hand-ischemia interventions (HR 0.36, 95% CI 0.18–0.71) with comparable long-term patency overall [68]. In patients with any cardiac concern, a forearm-first strategy limits the hemodynamic insult while preserving the fistula advantage.

Clinical Pearl

The LIMA trap. Patients with prior coronary artery bypass grafting using a left internal mammary artery (LIMA) graft are at particular risk when an ipsilateral upper extremity AV fistula is created or enlarged. The fistula creates a low-resistance steal pathway that diverts flow away from the LIMA and into the venous system — producing coronary ischemia despite patent grafts. Aala et al. (2017) reported a case of post-angioplasty hypotension from this mechanism, resolved by fistula banding [57]. Avoid ipsilateral AVF creation in patients with LIMA bypass grafts. If a fistula already exists on the LIMA side, echocardiography plus stress testing should be performed before any access intervention that would increase flow.

When to intervene on an existing high-flow fistula

The decision to band, revise, or ligate a functioning fistula is never taken lightly — the access represents the patient’s lifeline. But when the access is killing the heart, the calculus changes. Intervention should be considered when:

Access flow >2,000 mL/min on duplex or dilution measurement [55,60]
Qa/CO ratio >25–30% [55], [64]
Progressive RV dilation or declining TAPSE on serial echocardiography
New or worsening pulmonary hypertension (RVSP >50 mmHg) without alternative explanation
Symptomatic HOHF — dyspnea, edema, or ascites that improves with temporary fistula compression
Post-transplant with a functioning fistula no longer needed for dialysis — evaluate for elective ligation, as 25.7% required it in one transplant cohort [60]

Intervention options — all with the goal of reducing flow to no lower than 500–600 mL/min (the minimum for AVF patency):

Technique	Mechanism	Outcomes	Best For
Surgical banding	Constrictive cuff or plication to narrow outflow	100% technical success (n=31, proximal artery restriction plus distal artery ligation); flow reduction from 2,047 to 1,001 mL/min; 96.8% primary patency at 6 months [70]	Upper arm AVF with high flow; preserves access
RUDI (Revision Using Distal Inflow)	Converts inflow from brachial to radial/ulnar artery, increasing resistance	90–100% symptom resolution; primary patency 58–74% at 1 year [71]	Brachial-based AVF with steal or HOHF; adds forearm cannulation segment
DRIL (Distal Revascularization with Interval Ligation)	Ligates brachial artery distal to anastomosis + bypass to restore distal perfusion	98% symptom improvement; 100% fistula preservation [72]	Steal syndrome with functioning autologous fistula; requires major operation
Small-diameter graft interposition	Short 5-mm prosthetic graft placed in the outflow circuit	96% symptom resolution; 52.4% mean flow reduction; 3-year secondary patency 71.5% [73]	High-flow AVF where banding precision is difficult; preserves autologous access
Anastomotic revision (anastoplasty)	Narrows the arteriovenous anastomosis directly	Variable; precision critical — 0.5 mm diameter changes significantly affect outcomes [71]	Focal anastomotic dilation
Ligation	Definitive closure; eliminates the shunt entirely	Resolution of pulmonary hypertension [59], cardiac ascites [56], and HF symptoms [60]	Post-transplant; access no longer needed; life-threatening cardiac decompensation

Clinical Pearl

Tapered grafts do not prevent steal. The VQI database (n=3,608) found no difference in steal rates between tapered and nontapered grafts (4.1% vs 4.6%, p=0.58; HR 1.03, 95% CI 0.64–1.65) [74]. Paradoxically, some studies show flow rates through tapered grafts exceed those through standard grafts. KDOQI 2019 confirms no difference in patency or steal symptoms [53]. Do not rely on graft configuration for flow limitation or cardiac protection — no study shows that it works. Monitor flow and intervene early instead.

The catheter mortality trade-off. Catheter use carries substantially higher baseline risks compared to AVF: 53% higher all-cause mortality (RR 1.53), 112% higher fatal infection risk (RR 2.12), and 38% higher cardiovascular event risk (RR 1.38) [75]. These population-level risks must be weighed against the individual-level hemodynamic burden of AVF in patients with severe heart failure — where the fistula itself may be the driver of cardiac mortality. AVGs require higher minimum flow rates (600–700 mL/min) than AVFs (500–600 mL/min) to maintain patency, which limits how much flow can safely be reduced [71]. The clinical decision is not which access type is statistically safest across populations — it is which failure mode the individual patient can least afford.

8.4 Vaccination

HD patients have impaired humoral and cellular immune responses, resulting in lower seroconversion rates and faster antibody waning compared to the general population. Vaccination before dialysis initiation — when immune function is better preserved — produces superior responses [13,29].

Recommended vaccines for HD patients (each row checked against the current CDC page on 2026-09-26; the CDC adult schedule itself was last revised with a July 2, 2025 addendum [118]):

Vaccine	Schedule	HD-Specific Considerations
Hepatitis B	Recombivax HB dialysis formulation 40 mcg at 0, 1, 6 months, or Engerix-B 40 mcg (2 × 20 mcg) at 0, 1, 2, 6 months (see Section 4.2) [113,117,118]	Heplisav-B not established in adults on hemodialysis; anti-HBs 1-2 months after the series, then annually, booster below 10 mIU/mL [113,117]
Influenza	Annually, any age-appropriate vaccine (2026-27 vaccines are trivalent) [119]	Age ≥65: high-dose (HD-IIV3), recombinant (RIV3), or adjuvanted (aIIV3) preferred [119]; no dialysis-specific preference under 65
Pneumococcal	PCV15, PCV20, or PCV21; if PCV15, follow with PPSV23 [120]	Chronic renal failure is on CDC’s immunocompromising-condition list, so vaccinate at any adult age (universal at ≥50), and PPSV23 may follow PCV15 after 8 weeks rather than 1 year [118,120]
COVID-19	2026-2027 vaccine recommended for all adults ≥18 [121]	Moderately or severely immunocompromised patients follow CDC’s separate schedule (Table 2) [121]
RSV	Single dose for all adults ≥75, and for adults 50-74 at increased risk [122]	End-stage renal disease or dependence on hemodialysis is a listed risk condition, so HD patients qualify from age 50; not an annual vaccine [122]
Tdap	1 dose Tdap if never given, then Td or Tdap every 10 years [118]	Standard dosing
Shingles (Shingrix)	RZV 2 doses, 2-6 months apart, age ≥50 [123]	Also age ≥19 if immunodeficient or immunosuppressed (e.g., transplant immunosuppression), with dose 2 at 1-2 months [123]; ESKD itself is not listed as an indication

Clinical Warning

Vaccination before dialysis initiation is systematically superior. Hepatitis B seroconversion rates fall as CKD advances and are lowest in dialysis-dependent ESKD. For patients with progressive CKD approaching dialysis, vaccinate early — do not wait for dialysis initiation to begin the series [13,29].

8.5 Depression and Cognitive Screening

Depression: Depression affects 20-40% of HD patients — some studies report rates as high as 68% using self-report screening instruments [26]. It is independently associated with [26-28]:

Increased all-cause mortality (HR approximately 1.5-2.0)
Increased hospitalization rates
Missed dialysis treatments (a direct predictor of mortality)
Decreased quality of life and treatment adherence
Higher likelihood of withdrawal from dialysis

Screening: The PHQ-9 is validated for use in dialysis populations. The PHQ-2 serves as a rapid screen (2 questions); positive results should trigger full PHQ-9 assessment. Screening at HD initiation and at least annually is appropriate — more frequent screening (every 6 months) may be warranted given the high prevalence and fluctuating course [26-28].

Cognitive Impairment: Cognitive impairment is highly prevalent and underrecognized in HD populations, with estimates ranging from 30% to 80% depending on the assessment tool and definition used [47]. A 2025 study in Cureus documented the co-occurrence of cognitive dysfunction and depression in HD patients, highlighting significant unmet diagnostic needs [47].

Key considerations: - Uremic encephalopathy — cognitive deficits from retained uremic toxins; partially reversible with adequate dialysis - Vascular cognitive impairment — from chronic cerebral small vessel disease driven by hypertension, diabetes, and uremic vasculopathy - Dialysis-related cognitive fluctuations — cognitive performance is often worse in the hours following dialysis (osmotic shifts, hemodynamic instability) - Dementia prevalence — substantially higher in ESKD than age-matched controls

Screening with the Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE) should be considered at initiation and periodically, particularly in patients with functional decline, nonadherence, or unexplained behavioral changes.

Clinical Pearl

Depression and cognitive impairment are not comorbidities to note and ignore — they are treatment-modifying conditions. A depressed patient misses dialysis sessions. A cognitively impaired patient cannot manage their medications, fluid restriction, or dietary requirements. Screening changes management: SSRIs are safe in ESKD (adjust dosing for citalopram and escitalopram), and cognitive impairment may prompt caregiver involvement, simplified medication regimens, or reassessment of dialysis modality.

8.6 Dialysis Adequacy Monitoring

While not traditionally considered a “screening test,” dialysis adequacy is the most fundamental monitoring parameter in HD:

Single-pool Kt/V (spKt/V): Monthly; target >= 1.4 per session for thrice-weekly HD (KDOQI 2015) [51]
Urea reduction ratio (URR): Alternative adequacy metric; target >= 70%
Residual kidney function: Assess periodically in patients with residual urine output; contributes to overall solute clearance and may allow reduced dialysis prescription

8.6.1 Does Kt/V Actually Reduce Mortality? The Evidence Is Weaker Than You Think

The adequacy paradigm — monitor Kt/V monthly, target ≥1.4, investigate when it drops — is so deeply embedded in nephrology practice that questioning it feels like questioning dialysis itself. But the evidence that hitting a specific Kt/V target improves outcomes, rather than merely correlating with them, is remarkably thin.

The observational foundation

The entire Kt/V-mortality story begins with an observational study and a small randomized trial:

Owen et al. (1993, NEJM) [76] — The foundational analysis of 13,473 HD patients showing that URR correlated with mortality. Patients with URR <60% had higher death rates. This is the paper that launched the adequacy movement. But critically, it also demonstrated that serum albumin was 21 times more powerful as a mortality predictor than URR. The stronger signal was ignored in favor of the one that could be measured and adjusted monthly.
NCDS (1981) [77] — The National Cooperative Dialysis Study established that clearly inadequate dialysis (very high BUN, very low clearance) increased hospitalization. But this set a floor — it proved that too little dialysis is harmful. It did not prove that exceeding the minimum improves outcomes.

The leap from “very low Kt/V is bad” to “higher Kt/V is better” is the assumption the HEMO trial was designed to test. It failed.

The HEMO Trial — the definitive negative study

The HEMO Study (Eknoyan et al., 2002) [78] was a 2×2 factorial RCT enrolling 1,846 prevalent HD patients and randomizing them to:

Standard dose (achieved eKt/V 1.16, spKt/V 1.32) vs high dose (achieved eKt/V 1.53, spKt/V 1.71)
Low-flux vs high-flux membranes

The result was unambiguous: no significant difference in all-cause mortality between standard and high-dose groups (RR 0.96, 95% CI 0.84–1.10) [78]. No difference in the composites of cardiac hospitalization or death, infection hospitalization or death, or albumin decline or death. High-flux vs low-flux membranes also showed no benefit in the primary analysis.

Nearly 2,000 patients. A 2×2 factorial randomized design. The answer was no.

Why more Kt/V doesn’t help: urea is the wrong metric

The reason is now well understood. Kt/V measures urea clearance. Urea is a small (60 Da), freely diffusible, water-soluble molecule that crosses dialysis membranes easily. But the solutes that actually drive uremic toxicity and cardiovascular mortality are not urea:

Toxin Class	Examples	Molecular Weight	Dialysis Clearance
Small water-soluble (measured by Kt/V)	Urea, creatinine	60–113 Da	Excellent with conventional HD
Middle molecules	β2-microglobulin, FGF-23, IL-6	1,000–50,000 Da	Poor with conventional HD; improved with HDF
Protein-bound uremic toxins	p-Cresyl sulfate, indoxyl sulfate, TMAO	100–300 Da (bound)	Minimal clearance regardless of dose

Meyer et al. (2016) [79] analyzed samples from the HEMO trial and found that achieving higher Kt/V failed to meaningfully reduce non-urea solutes: p-cresyl sulfate showed 0% reduction, and methylguanidine showed only 22% reduction with the higher dose [79]. The solutes that Kt/V was supposed to be a surrogate for were not being cleared by the intervention it recommended.

This is the fundamental problem. Kt/V measures the removal of a molecule that is probably not the primary driver of uremic mortality, and interventions to increase Kt/V do not improve removal of the molecules that are.

Clinical Warning

The confounding problem with low Kt/V. Observational data consistently show that patients with low Kt/V have higher mortality. But low Kt/V is not just a marker of “not enough dialysis.” It is a marker of sickness: muscle wasting reduces urea generation (lower numerator), obesity increases volume of distribution (larger denominator), missed treatments reflect depression and nonadherence, and poor access flow delivers less clearance. A patient with low Kt/V is a patient who is sick — and making the Kt/V number higher by extending treatment time or increasing blood flow does not make the patient less sick if the underlying drivers are malnutrition, inflammation, and cardiovascular disease.

8.6.2 The Broader Problem: Quality Metrics That Predict Comorbidity but Don’t Improve Outcomes When Changed

The Kt/V story is not unique. It is the pattern for most “quality metrics” in dialysis — strong observational association with mortality, followed by randomized trials showing no benefit (or harm) from interventions designed to improve the metric. The table below summarizes the evidence:

Metric	Observational Association	Interventional Evidence	What It Actually Is
Kt/V / URR	Low Kt/V → higher mortality (Owen 1993)	HEMO trial: no benefit from higher Kt/V [78]. ADEMEX (PD): no benefit from higher peritoneal clearance [80]	Surrogate for overall health status, nutrition, treatment adherence, and access function
Albumin / Malnutrition	21x more powerful mortality predictor than URR (Owen 1993) [76]. HR 1.84 for albumin <3.5 g/dL [81]. Malnutrition on HD: pooled HR 1.53 (95% CI 1.38–1.70) in the 24-study HD subgroup of a 29-study, 11,063-patient meta-analysis [46]	Nutritional supplementation to raise albumin has not demonstrated mortality benefit. Albumin is driven by inflammation (CRP, IL-6), not nutrition alone	Inflammation marker misidentified as a nutritional target
Hgb	Anemia → higher mortality	Normal Hematocrit Trial (HD): halted early [103]; FDA-filed report showed higher death, RR 1.27 [104]. CHOIR, CREATE, TREAT (non-dialysis CKD) [82,83,84]: higher targets raised composite CV events (CHOIR) and stroke (TREAT); no single trial showed a significant mortality increase — the mortality signal is meta-analytic, RR 1.17 across nine trials [106]	ESA-driven normalization causes harm
PO4	High PO4 → higher mortality	No placebo-controlled RCT shows binder mortality benefit. IMPROVE-CKD (non-dialysis CKD) negative [85]	Marker of diet, residual function, bone disease
PTH	Extreme PTH (very high or very low) → higher mortality	EVOLVE trial: cinacalcet vs placebo failed its primary composite endpoint (death from any cause, MI, hospitalization for unstable angina, HF, or peripheral vascular event; HR 0.93, 95% CI 0.85–1.02) despite lowering PTH [86]	Marker of bone-mineral axis disease severity; treating the number does not fix the biology
Calcium	Extremes of calcium → higher mortality in observational studies	No RCT showing correction of calcium reduces mortality	Marker of bone-mineral homeostasis and vitamin D/PTH axis

The pattern is consistent: observational data identify a metric that correlates with bad outcomes → clinical guidelines set a target → interventions are deployed to hit the target → randomized trials fail to show that hitting the target improves survival. This is the classic reverse-causation trap: sick patients have bad numbers, and fixing the numbers does not fix the sickness.

Albumin deserves a closer look — it is far more important than Kt/V, but for reasons that complicate intervention

Owen’s 1993 data [76] showed albumin was 21 times more powerful as a mortality predictor than URR. A meta-analysis of 29 cohort studies (n = 11,063 dialysis patients) confirmed that malnutrition — assessed by GNRI, MIS, SGA, ISRNM criteria, or anthropometry — carries a pooled mortality HR of 1.49 (95% CI 1.36–1.64), with the hemodialysis subgroup showing an even stronger signal at HR 1.53 (95% CI 1.38–1.70, p < 0.0001) [46]. The effect was magnified in older patients (>60 years: HR 1.87) and in studies with shorter follow-up (≤36 months: HR 1.62), suggesting that malnutrition is an acute risk accelerator, not just a chronic comorbidity marker.

But the clinical question is not whether low albumin predicts death — it does, overwhelmingly. The question is what drives low albumin in dialysis patients, and whether correcting the albumin level changes outcomes. The answer is more complex than “feed the patient better”:

Driver of Low Albumin	Mechanism	Intervention	Does Fixing It Help?
Chronic inflammation (primary driver)	IL-6, TNF-α, CRP → increased hepatic albumin catabolism + decreased synthesis; acute phase response redirects hepatic protein production from albumin to CRP, fibrinogen, ferritin	Anti-inflammatory strategies (address infection, access issues, biocompatible membranes)	Potentially — but no RCT targeting inflammation has shown albumin-mediated mortality benefit
Protein-energy wasting	Inadequate caloric/protein intake → decreased albumin substrate; anorexia from uremic toxins, depression, dialysis-day fatigue	Oral nutritional supplements, intradialytic parenteral nutrition (IDPN), dietary counseling	IDPN raises albumin modestly but has not demonstrated mortality benefit in RCTs
Dialysate protein losses	0–2 g albumin per high-flux HD session; more with post-dilution HDF and some membranes [98]	Membrane selection; protein supplementation	Minimal impact — losses are modest relative to synthesis capacity
Metabolic acidosis	Uncorrected acidosis promotes muscle catabolism via ubiquitin-proteasome pathway	Bicarbonate supplementation; dialysate bicarbonate adjustment	Correcting acidosis improves nutritional markers but no mortality RCT
Volume overload	Proposed dilution and hepatic congestion — though kinetic studies found plasma-volume expansion does not contribute to hypoalbuminemia [90,91]	Ultrafiltration; dry weight optimization	Albumin rises with volume removal — but the rise reflects concentration, not production
Comorbid burden	Heart failure, liver disease, diabetes, malignancy → all lower albumin independently	Treat the underlying disease	Albumin is the downstream effect, not the cause

Kaysen’s landmark kinetic studies established the mechanistic hierarchy. Declines in serum albumin correlate with elevated acute-phase proteins (CRP, α1-acid glycoprotein, ceruloplasmin) but not with protein intake markers like normalized protein catabolic rate (nPCR) [89,90]. Nutritional variables primarily affect albumin synthesis, while inflammation increases albumin catabolism — and in well-dialyzed patients inflammation, not protein intake, was the principal cause of albumin decline [89,91]. Critically, low albumin predicts mortality primarily when accompanied by elevated CRP, suggesting that inflammation is the factor that converts low albumin from a nutritional finding into a death sentence [92,93].

The critical insight: CRP should accompany every albumin measurement. An albumin of 3.2 g/dL with a CRP of 0.5 mg/L is a nutritional problem. An albumin of 3.2 g/dL with a CRP of 45 mg/L is an inflammatory problem. The interventions are fundamentally different, but the dialysis quality reporting systems treat them identically — as a “low albumin” that needs nutritional supplementation. This is why population-level nutritional interventions fail: they are treating inflammation with protein shakes.

The phosphorus-albumin interaction adds another layer of complexity. The relationship between phosphorus and mortality is not a simple linear association — it is modified by albumin status. Patients with concurrent low phosphorus and low albumin have elevated mortality (the malnutrition-inflammation phenotype: sick patients don’t eat, so both phosphorus and albumin fall together). Patients with high phosphorus and high albumin also show increased risk (the non-compliant but well-nourished phenotype: eating too much, including phosphorus-rich protein). Phosphorus variability — not just absolute levels — independently predicts mortality, with higher coefficient of variation associated with worse outcomes [87,88]. This means the phosphorus “target” is not a number to hit but a pattern to stabilize, and it cannot be interpreted without knowing the albumin.

Clinical Pearl

The Owen paradox. Owen’s 1993 NEJM paper is cited as the foundation for Kt/V adequacy monitoring. But Owen’s own data showed albumin was 21 times more powerful as a mortality predictor than URR. The nephrology community built a monitoring infrastructure around the weaker predictor — because Kt/V could be adjusted monthly by modifying the dialysis prescription, while albumin reflected an inflammatory process that defied simple intervention. We chose the metric we could change, not the one that mattered most. This is not unique to nephrology. It is how surrogate endpoints become entrenched across medicine — convenience of measurement displaces strength of association.

What this means for practice

This is not an argument for abandoning Kt/V monitoring or letting patients receive clearly inadequate dialysis. There is a floor below which dialysis is insufficient (NCDS established this), and Kt/V remains a useful tool for detecting access dysfunction, recirculation, and treatment non-adherence — all actionable findings. Monthly Kt/V catches problems that matter.

But it is an argument for intellectual honesty about what we are measuring and why. We should:

Monitor Kt/V as a process metric, not an outcome metric. It tells us whether the machine is delivering what was prescribed. It does not tell us whether the patient is getting healthier.
Stop treating albumin as a nutritional target. Low albumin in a dialysis patient is an inflammation signal first, a nutrition signal second. CRP should accompany every albumin drawn.
Accept the HEMO result. A Kt/V of 1.4 is the minimum; exceeding it has no proven survival benefit. Spending clinical energy pushing Kt/V from 1.4 to 1.8 is low-value care.
Recognize the hemoglobin lesson. The Normal Hematocrit Trial (the one in hemodialysis patients) and CHOIR, CREATE, and TREAT (non-dialysis CKD) are the most expensive demonstration in nephrology that “making the number normal” is not the same as “making the patient better.” This lesson applies to every dialysis quality metric.
Invest in what HEMO couldn’t test — and what the evidence now supports.

8.6.3 High-Volume Hemodiafiltration: The Logical Conclusion

If Kt/V fails because urea is the wrong target, and if albumin falls because inflammation — not nutrition — is the primary driver, then the therapeutic response should address middle molecule clearance and systemic inflammation. High-volume hemodiafiltration (HDF) does both.

The mortality evidence is now positive. Two major RCTs have demonstrated what conventional HD adequacy trials could not:

Trial	Design	Key Result
ESHOL (2013)	n=906; high-efficiency online HDF vs high-flux HD	30% reduction in all-cause mortality (HR 0.70, 95% CI 0.53–0.92; NNT 8 to prevent one death per year); CV mortality HR 0.67 (95% CI 0.44–1.02, not significant) [94]
CONVINCE (2023)	n=1,360; high-dose HDF (≥23 L/session) vs high-flux HD	23% reduction in all-cause mortality (17.3% vs 21.9%; HR 0.77, 95% CI 0.65–0.93; ARR 4.6%, NNT 22 over a median 30 months; mean convection volume 25.3 L) [95]

HEMO asked: “Does more urea removal help?” Answer: no. ESHOL and CONVINCE asked: “Does convective removal of middle molecules help?” Answer: yes — but only at high convective volumes (≥23 L/session). The dose-response is to convective volume, not to Kt/V.

The anti-inflammatory mechanism. The CONTRAST trial demonstrated that over 3 years, CRP and IL-6 concentrations increased in patients on low-flux HD but remained stable in those on HDF — a difference of approximately 20% per year for CRP and 16% per year for IL-6, most pronounced in anuric patients; serum albumin fell equally in both arms [96]. HDF reduces inflammation through enhanced convective clearance of complement factor D, cytokines, and advanced glycation end products; use of ultrapure dialysate minimizing endotoxin exposure; and 30–40% higher β2-microglobulin clearance than high-flux HD [97].

This connects the two problems this section has identified:

Kt/V measures urea but the killers are middle molecules → HDF clears middle molecules by convection, not diffusion
Albumin falls because of inflammation, not malnutrition → HDF reduces inflammation (CRP, IL-6) while conventional HD allows it to progress
The paradox of albumin losses in HDF → HDF does increase dialysate albumin losses (0–2 g per session on high-flux HD; more on post-dilution HDF — above 5 g per session with some dialyzers and up to 24 g in one reported case [98]). But in malnourished, inflamed patients, the anti-inflammatory benefit may outweigh the albumin loss — patients on HDF who start with low albumin have been shown to improve their albumin levels in a 47-patient crossover study, likely because reducing inflammation allows hepatic synthesis to recover [99] — though in CONTRAST, albumin fell equally on HDF and HD [96]. Ward et al. (2019) posed the question directly: is mild hypoalbuminemia “a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?” The mortality data from ESHOL and CONVINCE suggest the answer is yes [100].

Clinical Pearl

HDF is not “better dialysis” — it is a different modality. Conventional HD optimizes diffusive clearance (small solutes). HDF optimizes convective clearance (middle molecules). Measuring HDF with Kt/V is like measuring a truck’s payload with a speedometer — it captures the wrong dimension. The relevant metric for HDF is convective volume per session, and the mortality benefit appears at ≥23 L/session. Programs that adopt HDF but fail to achieve this threshold may see no benefit — dose matters, but the dose is convective volume, not Kt/V.

Section Summary

Health maintenance in HD extends well beyond the disease-specific domains covered in earlier sections. Anemia monitoring (monthly CBC, iron studies every 1-3 months per KDIGO 2026 [101]) guides ESA and iron therapy. Protein-energy wasting affects 28-54% of dialysis patients [114] with a mortality HR of 1.49 [46] — monthly albumin and annual SGA are the minimum. Cardiovascular screening with echocardiography at initiation and every 1-3 years detects the progressive cardiomyopathy and valvular disease that drive the leading cause of death. Vaccination requires an HD-specific approach with high-dose formulations and pre-dialysis timing whenever possible. Depression (20-40% [26]) and cognitive impairment (30-80% [47]) are prevalent, undertreated, and treatment-modifying. Dialysis adequacy with monthly Kt/V rounds out the monitoring framework.

9. Comprehensive Screening Summary Table

Screening Test	Frequency in HD	Key Considerations
Lipid profile	At initiation only; no routine follow-up	Fire-and-forget: no LDL target, no titration, no serial monitoring. Same for primary and secondary prevention
Fish oil supplementation	Consider initiating for all HD patients	PISCES trial [25]: first large placebo-controlled CV prevention trial in dialysis to succeed; HR 0.57; ARR 12.9%, NNT 8 over up to 3.5 years
HbA1c	Not recommended as sole glycemic marker	KDIGO 2022 primary marker [33], but underestimates glycemia in HD; add CGM when discordant
Glycated albumin	Every 2-4 weeks if monitoring diabetes	Alternative lab marker that avoids red-cell bias; not endorsed as superior by KDIGO [33]; biased by dialysis modality, vintage, residual function, BMI [36]
CGM	Continuous (when available/covered)	Most direct glycemic tool; captures variability, hypo/hyperglycemia invisible to labs
Calcium, phosphorus	Every 1-3 months	Part of CKD-MBD management
Intact PTH	Every 3-6 months	Target 2-9x ULN; trends matter more than individual values
Alkaline phosphatase	Every 12 months	Marker of bone turnover; check more often if PTH elevated
25(OH) Vitamin D	At initiation; repeat as needed	Correct deficiency per general population guidelines
HCV screening	Every 6 months	Immunoassay or NAT; ALT monthly
HBV screening	At initiation; anti-HBs annually	Revaccinate if anti-HBs < 10 mIU/mL
TSH	At initiation; annually thereafter	High prevalence (11-20% [14], [16]); symptoms overlap with uremia; diagnose on TSH not free T3/T4
Renal ultrasound (ACKD/RCC)	Starting at 3 years on dialysis; then annually	CT for suspicious findings; nephrectomy if mass > 3 cm; SIR 4.7 for kidney cancer
Colonoscopy	Individualized	Primarily for transplant candidates; limited benefit if survival < 5 years; use FIT not guaiac FOBT
Mammography / PSA / Pap	Individualized	Per general population guidelines if transplant candidate with adequate expected survival
Echocardiography	At initiation; every 1-3 years	LV function, valvular calcification, pericardial disease, PH screen
ECG	At initiation; periodically	Electrolyte-driven arrhythmias, QTc prolongation
CBC	Monthly	ESA management; start ESA at Hb ≤9.0-10.0, target below 11.5 g/dL (KDIGO 2026 [101])
Iron studies (ferritin, TSAT)	Every 1-3 months (KDIGO 2026 [101])	Proactive IV iron; initiate at ferritin ≤500 and TSAT ≤30%, withhold at ferritin >700 or TSAT ≥40% [101]; TSAT more actionable than ferritin
Albumin	Monthly	Nutritional and inflammation marker; < 3.5 g/dL is a red flag
SGA (nutritional assessment)	Annually	Validated composite nutritional assessment tool
spKt/V	Monthly	Dialysis adequacy; target >= 1.4 per session
Depression screening (PHQ-9)	At initiation; annually (consider q6 months)	Prevalence 20-40% [26]; associated with mortality and missed treatments
Cognitive screening	At initiation; periodically	Prevalence 30-80% [47]; MoCA or MMSE; treatment-modifying
Vaccinations	Per ACIP schedule (HD-modified)	High-dose HBV, annual influenza, pneumococcal, COVID, RSV >=50 (HD is a risk condition), Tdap, Shingrix >=50 [117-123]

10. Summary and Key Recommendations

Lipid management follows a “fire-and-forget” strategy. Statins should not be newly initiated in prevalent dialysis patients — 4D, AURORA, and the SHARP dialysis subgroup were all negative. KDIGO 2013 remains the operative guidance (KDIGO 2024 excludes dialysis). Continue statins started pre-dialysis. The PISCES trial (Lok et al., N Engl J Med 2026; HR 0.57, 95% CI 0.47–0.70, p<0.001; at least one event 20.8% vs 33.7%, ARR 12.9%, NNT 8 over up to 3.5 years) represents a paradigm shift: fish oil is the first supplement to reduce cardiovascular events against placebo in a large trial of maintenance HD patients [25].
HbA1c is unreliable in HD. It underestimates true glycemia by approximately 25 mg/dL of mean glucose, yet KDIGO 2022 keeps it as the primary marker and supports CGM when it is discordant [33]. Glycated albumin is an alternative that avoids red-cell bias — but it carries its own [36]. CGM is the most direct glycemic tool. The “burnt-out diabetes” phenomenon is an artifact, not a remission. The 2026 Zelnick prospective study confirms that no single lab marker can be trusted in isolation.
CKD-MBD monitoring follows KDIGO 2017: calcium and phosphorus every 1-3 months, PTH every 3-6 months, ALP annually. Trends over single values. No RCT demonstrates mortality benefit from phosphate binder therapy.
Hepatitis screening is critical for infection control and transplant planning. HCV every 6 months, HBV at initiation with annual anti-HBs monitoring. DAAs achieve approximately 97% SVR in ESKD [12]. Vaccine seroconversion is markedly reduced in HD — use high-dose formulations and vaccinate early [113].
Thyroid screening (TSH at initiation, annually) is reasonable given 11-20% prevalence [14,16], symptom overlap with uremia, and cardiovascular association. Diagnose on TSH, not FT3/FT4. Low T3 syndrome is common and does not require treatment.
Cancer screening must be individualized — ASN recommends against routine screening in patients with limited life expectancy [18]. Transplant candidates follow general population guidelines. The 2024 CJASN review places nephrologists at the center of this decision.
ACKD/RCC surveillance is critically underrecognized. Begin ultrasound at 3 years of dialysis. Annual surveillance for established ACKD. CT for suspicious findings. ACKD develops in >90% of patients on dialysis >10 years and carries up to 50-fold increased RCC risk [21].
Cardiovascular screening includes echocardiography at initiation and every 1-3 years. Fish oil supplementation should be considered [25]. Pulmonary hypertension is common and underdiagnosed. Right heart assessment is essential — AV fistula-related high-output cardiac failure is underrecognized, and access flows exceeding 1.5–2.0 L/min or consuming >25–30% of cardiac output [55] are associated with LVH, RV failure, and pulmonary hypertension. Vascular access selection must account for cardiac status: forearm-first strategies and grafts limit hemodynamic burden in patients with reduced EF or RV dysfunction [52-61].
Anemia and nutrition monitoring are fundamental — monthly CBC and albumin, iron studies every 1-3 months (KDIGO 2026 [101]), annual SGA. Protein-energy wasting carries a mortality HR of 1.49.
Depression (20-40%) and cognitive impairment (30-80%) are prevalent, undertreated, and treatment-modifying. PHQ-9 and MoCA are validated screening tools. Screening changes management — SSRIs are safe in ESKD, and cognitive impairment may prompt modality reassessment.
Vaccination requires an HD-specific approach. High-dose hepatitis B formulations, annual anti-HBs monitoring, and pre-dialysis vaccination timing are evidence-based strategies to overcome the impaired immune response in ESKD.

References

Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis (4D Study). N Engl J Med. 2005;353(3):238-248. PMID: 16034009
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis (AURORA). N Engl J Med. 2009;360(14):1395-1407. PMID: 19332456
KDIGO Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in CKD. Kidney Int Suppl. 2013;3:259-305.
Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):684-701. PMID: 38519239
Alarcon-Casas Wright L, Hirsch IB. The challenge of the use of glycemic biomarkers in diabetes: reflecting on hemoglobin A1C, 1,5-anhydroglucitol, and the glycated proteins fructosamine and glycated albumin. Diabetes Spectr. 2012;25(3):141-148.
Bomholt T, Rix M, Almdal T, et al. The accuracy of hemoglobin A1c and fructosamine evaluated by long-term continuous glucose monitoring in patients with type 2 diabetes undergoing hemodialysis. Blood Purif. 2022;51(7):608-616. PMID: 34583354
Zelnick LR, Batacchi ZO, Ahmad I, et al. Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease. Diabetes Care. 2020;43(10):2379-2387. PMID: 32788282
Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A1C levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73(9):1062-1068. PMID: 18288102
Kaminski CY, Galindo RJ, Navarrete JE, et al. Assessment of glycemic control by continuous glucose monitoring, hemoglobin A1c, fructosamine, and glycated albumin in patients with end-stage kidney disease and burnt-out diabetes. Diabetes Care. 2024;47(2):267-271. PMID: 38085705
KDIGO CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Kidney Int Suppl. 2017;7(1):1-59. PMID: 30675420
Ketteler M, Bover J, Brandenburg A, et al. CKD-mineral and bone disorder: conclusions from a KDIGO Controversies Conference. Kidney Int. 2025;107(3):405-423. PMID: 39864017
KDIGO Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. 2022;102(6S):S129-S205. PMID: 36410841
Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations – United States, 2023. MMWR Recomm Rep. 2023;72(1):1-25. PMID: 36893044
Cuna V, Menghi V, Comai G, et al. Functional abnormalities and thyroid nodules in patients with end-stage renal disease. In Vivo. 2017;31(6):1203-1208. PMID: 29102947
Rhee CM, You AS, Nguyen DV, et al. Thyroid status and mortality in a prospective hemodialysis cohort. J Clin Endocrinol Metab. 2017;102(5):1568-1577. PMID: 28324018
Lo JC, Beck GJ, Kaysen GA, et al. Thyroid function in end stage renal disease and effects of frequent hemodialysis. Hemodial Int. 2017;21(4):534-541. PMID: 28301073
Rhee CM, Budoff M, Brent G, et al. Serum thyrotropin elevation and coronary artery calcification in hemodialysis patients. Cardiorenal Med. 2022;12(3):106-116. PMID: 35551382
Williams AW, Dwyer AC, Eddy AA, et al. Critical and honest conversations: the evidence behind the “Choosing Wisely” campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012;7(10):1664-1672. PMID: 22977214 (ASN Choosing Wisely recommendation 1: “Don’t perform routine cancer screening for dialysis patients with limited life expectancies without signs or symptoms.”)
Carlos CA, McCulloch CE, Hsu CY, et al. Colon cancer screening among patients receiving dialysis in the United States: are we choosing wisely? J Am Soc Nephrol. 2017;28(8):2521-2528. PMID: 28336719
Jayaram D, Golestaneh L. Cancer screening among patients with kidney failure requiring hemodialysis: where we are and where we are going. Clin J Am Soc Nephrol. 2024;19(12):1521-1523. PMID: 39482278
Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995;26(1):1-12. PMID: 7611240
McCarthy MR, Gupta S, Erickson LA. Acquired cystic disease-associated renal cell carcinoma. Mayo Clin Proc. 2023;98(4):637-638. PMID: 37019519
Ishikawa I, Saito Y, Shikura N, et al. Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis. 1990;16(5):452-458. PMID: 2239936
Ye J, Ran B, Huang Y, et al. Incidence of major urological cancers in patients on dialysis: a systematic review and meta-analysis. World J Surg Oncol. 2025;23(1):118. PMID: 40186281
Lok CE, Farkouh M, Hemmelgarn BR, et al. Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis (PISCES). N Engl J Med. 2026;394(2):128-137. PMID: 41201837
Yuan C, Chang F, Zhai H. Integrative approaches to depression in end-stage renal disease: insights into mechanisms, impacts, and pharmacological strategies. Front Pharmacol. 2025;16:1559038. PMID: 40297143
Zhao J, Wu M, Zhang L, et al. Higher levels of depression are associated with increased all-cause mortality in individuals with chronic kidney disease: a prospective study based on NHANES. J Affect Disord. 2025;390:119785. PMID: 40609657
Depression in kidney failure patients. In: Handbook of Dialysis Therapy. Springer; 2025:127.
Flythe JE, Watnick S. Dialysis for chronic kidney failure: a review. JAMA. 2024;332(18):1559-1573. PMID: 39356511
Tonelli M, Wanner C; KDIGO Lipid Guideline Development Work Group. Lipid management in chronic kidney disease: synopsis of the KDIGO 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182-189. PMID: 24323134
Wanner C, Tonelli M; KDIGO Lipid Guideline Development Work Group. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-1309. PMID: 24552851
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (SHARP). Lancet. 2011;377(9784):2181-2192. PMID: 21663949
KDIGO 2022 Diabetes Management in CKD Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. PMID: 36272764
de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974-989. PMID: 36202661
Rhee CM, Gianchandani RY, Kerr D, et al. Consensus report on the use of continuous glucose monitoring in chronic kidney disease and diabetes. J Diabetes Sci Technol. 2025;19(1):217-245. PMID: 39611379
Zelnick LR, Trikudanathan S, Hall YN, et al. Accuracy, variability, and bias of glycemic biomarkers in patients treated with maintenance dialysis. Diabetes Care. 2026;49(5):835-842. PMID: 41805834
Gan T, Liu X, Xu G. Glycated albumin versus HbA1c in the evaluation of glycemic control in patients with diabetes and CKD. Kidney Int Rep. 2018;3(3):542-554. PMID: 29854962
Luu HH, Ryan J, Toussaint ND. A narrative review of routine haematological and biochemical parameter monitoring in maintenance haemodialysis patients and comparison of clinical guidelines. BMC Nephrol. 2026;27(1):19. PMID: 41484839
Brenta G, et al. Kidney diseases and the thyroid: interactions and consequences. Nat Rev Endocrinol. 2026;22(4):228-241. PMID: 41249474
Liu C, Zhu X, Wang D, et al. Impaired sensitivity to thyroid hormones is associated with all-cause and cause-specific mortality among chronic kidney disease patients. Ren Fail. 2024;46(2):2433178. PMID: 39689980
[REFERENCE WITHDRAWN — original citation hallucinated; PMID: 24899610 is an unrelated pediatric GI paper. Colorectal cancer screening in dialysis is covered by Refs 19, 20, 42, 49.]
Kiberd B. Colorectal cancer screening in kidney disease patients: working backwards. Nephrol Dial Transplant. 2013;28(4):774-777. PMID: 23129825
Abdelwahed R, Tretiakova M. Acquired cystic disease associated renal cell carcinoma. PathologyOutlines.com. 2026.
Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1):S11-S103. PMID: 32301874
KDIGO 2012 Clinical Practice Guideline for Anemia in CKD. Kidney Int Suppl. 2012;2(4):279-335. (Superseded by KDIGO 2026 [101]; retained for history.)
Rashid I, Sahu G, Tiwari P, et al. Malnutrition as a potential predictor of mortality in chronic kidney disease patients on dialysis: a systematic review and meta-analysis. Clin Nutr. 2024;43(7):1760-1769. PMID: 38852509
Gautam S, Kiran UV. Co-occurrence of cognitive dysfunction and depressive disorders in hemodialysis patients: demographic patterns and unmet diagnostic needs. Cureus. 2025;17(12):e99003. PMID: 41527644
Shafi T, Sozio SM, Plantinga LC, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 2013;36(6):1522-1533. PMID: 23250799
Rosner MH. Cancer screening in patients undergoing maintenance dialysis: who, what, and when. Am J Kidney Dis. 2020;76(4):558-566. PMID: 32305205
Kim DH, Cho A, Park HC, et al. Regular laboratory testing and patient survival among patients undergoing maintenance hemodialysis: a Korean nationwide cohort study. Sci Rep. 2023;13(1):18360. PMID: 37884647
Rocco MV, Daugirdas JT, Depner TA, et al. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis. 2015;66(5):884-930. PMID: 26498416
Lok CE, Huber TS, Orchanian-Cheff A, et al. Arteriovenous access for hemodialysis: a review. JAMA. 2024;331(15):1307-1317. PMID: 38497953
Lok CE, Yuo T, Lee T, et al. Hemodialysis vascular access: core curriculum 2025. Am J Kidney Dis. 2025;85(2):236-252. PMID: 39625430
Malik J, Valerianova A, Pesickova SS, et al. CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol. J Vasc Access. 2024;25(1):294-302. PMID: 35676802
Mondal Z, Jalalzadeh M, Khalil S, et al. Hemodialysis access blood flow and cardiopulmonary outcomes. Cureus. 2025;17(12):e98259. PMID: 41480452
Kolman M, Kavinsky L, Soble J, et al. Arteriovenous fistula-associated ascites. Semin Dial. 2025;38(5-6):361-364. PMID: 41491640
Aala A, Sharif S, Parikh L, et al. High-output cardiac failure and coronary steal with an arteriovenous fistula. Am J Kidney Dis. 2018;71(6):896-903. PMID: 29277506
Takahashi D, Katayama K, Iyoda Y, et al. High-flow arteriovenous fistula in X-linked Alport syndrome: a case report. Front Med (Lausanne). 2023;10:1227283. PMID: 37928459
Hartley JL, Sharma A, Taha L, et al. High-output cardiac failure secondary to high-output arteriovenous fistula: investigations, management and definitive treatment. BMJ Case Rep. 2020;13(2):e233669. PMID: 32111713
Schier T, Göbel G, Bösmüller C, et al. Incidence of arteriovenous fistula closure due to high-output cardiac failure in kidney-transplanted patients. Clin Transplant. 2013;27(6):858-865. PMID: 24118251
Fisher AT, Mulaney-Topkar B, Sheehan BM, et al. Association between heart failure and arteriovenous access patency in patients with end-stage renal disease on hemodialysis. J Vasc Surg. 2024;79(5):1187-1194. PMID: 38157996
Reddy YNV, Obokata M, Dean PG, et al. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end-stage renal disease. Eur Heart J. 2017;38(24):1913-1923. PMID: 28329100
Fornazarič D, Gubenšek J, Antonič M, Cvijić M, Pajek J. Vascular Access for Hemodialysis and Right Ventricular Remodeling: A Prospective Echocardiographic Study. J Clin Med. 2025;14(15):5565. PMID: 40807186
Kim Y, Kim JH, Woo J, et al. Hemodynamic adaptation and cardiac effects of high-flow arteriovenous access in hemodialysis patients: a prospective study. J Clin Med. 2025;14(13):4556. PMID: 40648930
Tripathi A, Hanten B, Shafiq M, et al. Incidence and outcomes of high-output heart failure in patients with arteriovenous fistula: a single-center retrospective cohort study. J Clin Med. 2025;14(21):7689. PMID: 41227083
Zamboli P, Lucà S, Borrelli S, et al. High-flow arteriovenous fistula and heart failure: could the indexation of blood flow rate and echocardiography have a role in the identification of patients at higher risk? J Nephrol. 2018;31(6):975-983. PMID: 29357085
Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant. 2008;23(1):282-287. PMID: 17942475
Manchella MK, Appah-Sampong A, Ruan M, et al. Longitudinal outcomes of forearm versus upper arm arteriovenous fistulas. J Vasc Surg. 2025;82(3):1048-1057. PMID: 40490163
Chuang MK, Chang CH, Chan CY. The effect of haemodialysis access types on cardiac performance and morbidities in patients with symptomatic heart disease. PLoS One. 2016;11(2):e0148278. PMID: 26848850
Huang XM, Yu F, Wang Y, et al. Effect of proximal artery restriction on flow reduction and cardiac function in hemodialysis patients with high-flow arteriovenous fistulas. J Vasc Surg. 2023;78(2):526-533. PMID: 37086822
Hurwitz M, Dang QA, Scali S, et al. Diagnosis and management of hemodialysis access complications: a review. JAMA Surg. 2026;161(3):296-303. PMID: 41191344
Leake AE, Winger DG, Leers SA, Gupta N, Dillavou ED. Management and outcomes of dialysis access-associated steal syndrome. J Vasc Surg. 2015;61(3):754-760. PMID: 25499703
Hashimoto T, Akagi D, Yamamoto S, et al. Short interposition with a small-diameter prosthetic graft for flow reduction of a high-flow arteriovenous fistula. J Vasc Surg. 2021;73(1):285-290. PMID: 32473337
Roberts L, Farber A, Jones DW, et al. Tapered arteriovenous grafts do not provide significant advantage over nontapered grafts in upper extremity dialysis access. J Vasc Surg. 2019;69(5):1552-1558. PMID: 30583896
Ravani P, Palmer SC, Oliver MJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol. 2013;24(3):465-473. PMID: 23431075
Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329(14):1001-1006. PMID: 8366899
Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305(20):1176-1181. PMID: 7027040
Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010-2019. PMID: 12490682
Meyer TW, Sirich TL, Fong KD, et al. Kt/Vurea and nonurea small solute levels in the Hemodialysis Study. J Am Soc Nephrol. 2016;27(11):3469-3478. PMID: 27026365
Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307-1320. PMID: 11961019
Öneç K, Altun G, Sav T. Baseline serum albumin for long-term risk stratification in maintenance hemodialysis patients: a retrospective cohort study. J Clin Med. 2026;15(1):333. PMID: 41517580
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. PMID: 17108343
Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084. PMID: 17108342
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032. PMID: 19880844
Toussaint ND, Pedagogos E, Lioufas NM, et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020;31(11):2653-2666. PMID: 32917784
Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-2494. PMID: 23121374
Zhu M, Dou L, Zhu M, et al. Variability of serum phosphorus and its association with mortality among hemodialysis patients. Clin Nephrol. 2018;90(2):79-86. PMID: 29578398
Zitt E, Lamina C, Sturm G, et al. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. Clin J Am Soc Nephrol. 2011;6(11):2650-2656. PMID: 21903986
Kaysen GA, Dubin JA, Müller HG, et al. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 2004;65(4):1408-1415. PMID: 15086482
Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol. 1998;9(12):2368-2376. PMID: 9848794
Kaysen GA, Dubin JA, Müller HG, et al. Relationships among inflammation, nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002;61(6):2240-2249. PMID: 12028466
Mukai H, Villafuerte H, Qureshi AR, Lindholm B, Stenvinkel P. Serum albumin, inflammation, and nutrition in end-stage renal disease: C-reactive protein is needed for optimal assessment. Semin Dial. 2018;31(5):435-439. PMID: 29926516
Alves FC, Sun J, Qureshi AR, et al. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS One. 2018;13(1):e0190410. PMID: 29298330
Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24(3):487-497. PMID: 23411788
Blankestijn PJ, Vernooij RWM, Hockham C, et al. Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. N Engl J Med. 2023;389(8):700-709. PMID: 37326323
den Hoedt CH, Bots ML, Grooteman MP, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int. 2014;86(2):423-432. PMID: 24552852
Canaud B, Vienken J, Ash S, Ward RA. Hemodiafiltration to address unmet medical needs in ESKD patients. Clin J Am Soc Nephrol. 2018;13(9):1435-1443. PMID: 29511057
Cuvelier C, Tintillier M, Migali G, Van Ende C, Pochet JM. Albumin losses during hemodiafiltration: all dialyzers are not created equal — a case report. BMC Nephrol. 2019;20(1):392. PMID: 31660886
Aichi M, Kuragano T, Iwasaki T, et al. Hemodiafiltration improves low levels of health-related quality of life (QoL) and nutritional conditions of hemodialysis patients. ASAIO J. 2022;68(2):297-302. PMID: 34172640
Ward RA, Beck W, Bernardo AA, et al. Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins? Nephrol Dial Transplant. 2019;34(6):901-907. PMID: 30102329
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1S):S1-S99. PMID: 41485812
Babitt JL, Berns JS, Bozkurt B, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56. PMID: 41485807
Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590. PMID: 9718377
Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82(2):235-241. PMID: 22437411
Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16(7):2180-2189. PMID: 15901766
Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381-388. PMID: 17276778
Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis (PIVOTAL). N Engl J Med. 2019;380(5):447-458. PMID: 30365356
Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. J Am Soc Nephrol. 2020;31(5):1118-1127. PMID: 32253271
Amgen Inc. EPOGEN (epoetin alfa) injection, prescribing information. Revised April 2024 (FDA Reference ID 5373326). Not PubMed-indexed. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103234s5378lbl.pdf
Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52(1):217-222. PMID: 9211366
Akebia Therapeutics. VAFSEO (vadadustat) tablets, prescribing information, revised March 2024 (FDA Reference ID 5354686). Not PubMed-indexed. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215192s000lbl.pdf
Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391-398. PMID: 18094682
Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43. PMID: 11349873
Carrero JJ, Thomas F, Nagy K, et al. Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies from the International Society of Renal Nutrition and Metabolism. J Ren Nutr. 2018;28(6):380-392. PMID: 30348259
Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438-1444. PMID: 12742278
Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-S107. PMID: 32829751
Centers for Disease Control and Prevention. Hepatitis B vaccine administration (health care providers). Page last updated September 18, 2025; accessed 2026-09-26. https://www.cdc.gov/hepatitis-b/hcp/vaccine-administration/index.html
Centers for Disease Control and Prevention. Adult immunization schedule notes and schedule by medical condition, 2025 (addendum July 2, 2025); accessed 2026-09-26. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html
Centers for Disease Control and Prevention. Interim clinical considerations for the use of seasonal influenza vaccines in the United States, 2026-2027 season. September 1, 2026; accessed 2026-09-26. https://www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html
Centers for Disease Control and Prevention. Pneumococcal vaccine recommendations. Page last updated February 25, 2026; accessed 2026-09-26. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
Centers for Disease Control and Prevention. 2026-2027 COVID-19 vaccination guidance for people who are not immunocompromised. September 23, 2026; accessed 2026-09-26. https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html
Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Page last updated February 24, 2026; accessed 2026-09-26. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html
Centers for Disease Control and Prevention. Shingles vaccine recommendations. Page last updated October 22, 2024; accessed 2026-09-26. https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
42 CFR §494.30 — Condition: Infection control (incorporates CDC MMWR 2001;50(RR-05) pages 18-28 “with the exception of screening for hepatitis C”). https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-494/subpart-B/section-494.30
Recombivax HB (hepatitis B vaccine, recombinant). Prescribing information. Merck Sharp & Dohme; November 2025. DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5bd99e4-569d-48d5-ba75-16e69f8c409a

Review prepared by Andrew Bland, MD, FACP, FAAP – Medical Associates Department of Nephrology

Last updated: April 2026; §8.1 anemia content (with the matching Executive Summary, §8.6.2, §9, and §10 lines) updated to KDIGO 2026 on 2026-09-26; full reference check applied 2026-09-26 (every PMID resolved against PubMed, two wrong PMIDs and citation details corrected, claims matched to sources, references 112-116 added); second pass 2026-09-26: §4.1 KDIGO 2022 HCV schedule verified against the full guideline text, SVR and transplant-timing wording corrected, §4.2 and §8.4 vaccine rows re-sourced to current CDC pages (RSV at 50 or older for HD patients, PCV21 added, COVID-19 2026-27 for all adults), references 117-125 added, and glycated-albumin wording in the Executive Summary, §2 summary, §9, and §10 aligned with the corrected §2.5 box; §1.6 UpToDate Grade 2B verified 2026-09-26

Verified against OpenEvidence, UpToDate, and UIC Library sources (April 2026)